A	O
critical	O
role	O
of	O
the	O
p75	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
p75TNF-R	B-protein
)	O
in	O
organ	O
inflammation	O
independent	O
of	O
TNF	B-protein
,	O
lymphotoxin	B-protein
alpha	I-protein
,	O
or	O
the	O
p55TNF-R	B-protein
.	I-protein

Despite	O
overwhelming	O
evidence	O
that	O
enhanced	O
production	O
of	O
the	O
p75	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
p75TNF-R	B-protein
)	O
accompanies	O
development	O
of	O
specific	O
human	O
inflammatory	O
pathologies	O
such	O
as	O
multi-organ	O
failure	O
during	O
sepsis	O
,	O
inflammatory	O
liver	O
disease	O
,	O
pancreatitis	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
or	O
AIDS	O
,	O
the	O
function	O
of	O
this	O
receptor	O
remains	O
poorly	O
defined	O
in	O
vivo	O
.	O

We	O
show	O
here	O
that	O
at	O
levels	O
relevant	O
to	O
human	O
disease	O
,	O
production	O
of	O
the	O
human	B-protein
p75TNF-R	I-protein
in	O
transgenic	O
mice	O
results	O
in	O
a	O
severe	O
inflammatory	O
syndrome	O
involving	O
mainly	O
the	O
pancreas	O
,	O
liver	O
,	O
kidney	O
,	O
and	O
lung	O
,	O
and	O
characterized	O
by	O
constitutively	O
increased	O
NF-kappaB	B-protein
activity	O
in	O
the	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	I-cell_type
compartment	O
.	O

This	O
process	O
is	O
shown	O
to	O
evolve	O
independently	O
of	O
the	O
presence	O
of	O
TNF	B-protein
,	O
lymphotoxin	B-protein
alpha	I-protein
,	O
or	O
the	O
p55TNF-R	B-protein
,	O
although	O
coexpression	O
of	O
a	O
human	B-DNA
TNF	I-DNA
transgene	I-DNA
accelerated	O
pathology	O
.	O

These	O
results	O
establish	O
an	O
independent	O
role	O
for	O
enhanced	O
p75TNF-R	B-protein
production	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
disease	O
and	O
implicate	O
the	O
direct	O
involvement	O
of	O
this	O
receptor	O
in	O
a	O
wide	O
range	O
of	O
human	O
inflammatory	O
pathologies	O
.	O

A	NULL
Critical	NULL
Role	NULL
of	NULL
the	NULL
p75	NULL
Tumor	NULL
Necrosis	NULL
Factor	NULL
Receptor	NULL
(	NULL
p75TNF-R	NULL
)	NULL
in	NULL
Organ	NULL
Inflammation	NULL
Independent	NULL
of	NULL
TNF	NULL
,	NULL
Lymphotoxin	NULL
«	NULL
,	NULL
or	NULL
the	NULL
pSSTNF-R	NULL
By	NULL
Eleni	NULL
Douni	NULL
and	NULL
George	NULL
Kollias	NULL
From	NULL
the	NULL
Department	NULL
of	NULL
Molecular	NULL
Genetics	NULL
Hellenic	NULL
Pasteur	NULL
Institute	NULL
115	NULL
21	NULL
A	NULL
thens	NULL
Hellas	NULL
Sum	NULL
m	NULL
ary	NULL
Despite	NULL
overwhelming	NULL
evidence	NULL
that	NULL
enhanced	NULL
production	NULL
of	NULL
the	NULL
p75	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
(	NULL
p75TNF-R	NULL
)	NULL
accompanies	NULL
development	NULL
of	NULL
specific	NULL
human	NULL
inflammatory	NULL
pathologies	NULL
such	NULL
as	NULL
multi-organ	NULL
failure	NULL
during	NULL
sepsis	NULL
,	NULL
inflammatory	NULL
liver	NULL
disease	NULL
,	NULL
pancreatitis	NULL
,	NULL
respiratory	NULL
distress	NULL
syndrome	NULL
,	NULL
or	NULL
AIDS	NULL
,	NULL
the	NULL
function	NULL
of	NULL
this	NULL
receptor	NULL
remains	NULL
poorly	NULL
defined	NULL
in	NULL
vivo	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
at	NULL
levels	NULL
relevant	NULL
to	NULL
human	NULL
disease	NULL
,	NULL
production	NULL
of	NULL
the	NULL
human	NULL
p75TNF-R	NULL
in	NULL
transgenic	NULL
mice	NULL
results	NULL
in	NULL
a	NULL
severe	NULL
inflammatory	NULL
syndrome	NULL
involving	NULL
mainly	NULL
the	NULL
pancreas	NULL
,	NULL
liver	NULL
,	NULL
kidney	NULL
,	NULL
and	NULL
lung	NULL
,	NULL
and	NULL
characterized	NULL
by	NULL
constitutively	NULL
increased	NULL
NF-KB	NULL
activity	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
compartment	NULL
.	NULL

This	NULL
process	NULL
is	NULL
shown	NULL
to	NULL
evolve	NULL
independently	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
TNF	NULL
,	NULL
lymphotoxin	NULL
«	NULL
,	NULL
or	NULL
the	NULL
pS5TNF-R	NULL
,	NULL
although	NULL
coexpression	NULL
of	NULL
a	NULL
human	NULL
TNF	NULL
transgene	NULL
accelerated	NULL
pathology	NULL
.	NULL

These	NULL
results	NULL
establish	NULL
an	NULL
independent	NULL
role	NULL
for	NULL
enhanced	NULL
p75TNF-R	NULL
production	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
inflammatory	NULL
disease	NULL
and	NULL
implicate	NULL
the	NULL
direct	NULL
in	NULL
volvement	NULL
of	NULL
this	NULL
receptor	NULL
in	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
human	NULL
inflammatory	NULL
pathologies	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
T	NULL
umor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
a	NULL
potent	NULL
proinflammatory	NULL
molecule	NULL
involved	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
chronic	NULL
local	NULL
or	NULL
systemic	NULL
inflammation	NULL
in	NULL
vivo	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
TNF	NULL
are	NULL
signaled	NULL
via	NULL
two	NULL
cell	NULL
surface	NULL
receptors	NULL
(	NULL
TNF-R	NULL
)	NULL
,	NULL
designated	NULL
p55	NULL
and	NULL
p75TNF-R	NULL
,	NULL
which	NULL
are	NULL
capable	NULL
of	NULL
mediating	NULL
,	NULL
either	NULL
in	NULL
cooperation	NULL
or	NULL
indepen-dently	NULL
,	NULL
a	NULL
wide	NULL
spectrum	NULL
of	NULL
cellular	NULL
responses	NULL
ranging	NULL
from	NULL
direct	NULL
cytotoxicity	NULL
or	NULL
apoptosis	NULL
to	NULL
cellular	NULL
proliferation	NULL
and	NULL
differentiation	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

Soluble	NULL
forms	NULL
of	NULL
the	NULL
two	NULL
TNF-R	NULL
s	NULL
(	NULL
sTNF-R	NULL
)	NULL
,	NULL
which	NULL
represent	NULL
the	NULL
extracellular	NULL
portions	NULL
of	NULL
membrane-associated	NULL
TNF-R	NULL
s	NULL
and	NULL
are	NULL
shed	NULL
from	NULL
them	NULL
by	NULL
proteolytic	NULL
partition	NULL
,	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
serum	NULL
and	NULL
urine	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Using	NULL
TNF	NULL
or	NULL
TNF-R	NULL
knockout	NULL
mice	NULL
it	NULL
has	NULL
recently	NULL
been	NULL
demonstrated	NULL
that	NULL
the	NULL
TNF/	NULL
pSSTNF-R	NULL
pair	NULL
is	NULL
essential	NULL
for	NULL
many	NULL
physiological	NULL
processes	NULL
such	NULL
as	NULL
lymphoid	NULL
organ	NULL
architecture	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
,	NULL
immune	NULL
cell	NULL
activation	NULL
and	NULL
trafficking	NULL
(	NULL
8	NULL
)	NULL
,	NULL
and	NULL
host	NULL
defence	NULL
against	NULL
bacterial	NULL
(	NULL
6	NULL
,	NULL
9	NULL
,	NULL
10	NULL
)	NULL
or	NULL
viral	NULL
infections	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
a	NULL
dominant	NULL
role	NULL
of	NULL
the	NULL
pS5TNF-R	NULL
is	NULL
also	NULL
apparent	NULL
in	NULL
several	NULL
TNF-mediated	NULL
pa-thologies	NULL
,	NULL
including	NULL
endotoxemic	NULL
shock	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TNF-sensitizing	NULL
agents	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
,	NULL
or	NULL
in	NULL
disease	NULL
models	NULL
where	NULL
constitutively	NULL
produced	NULL
(	NULL
12-16	NULL
)	NULL
or	NULL
acutely	NULL
administered	NULL
levels	NULL
of	NULL
TNF	NULL
are	NULL
pathogenic	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
using	NULL
similar	NULL
assay	NULL
systems	NULL
,	NULL
there	NULL
has	NULL
been	NULL
very	NULL
little	NULL
evidence	NULL
for	NULL
a	NULL
specific	NULL
role	NULL
for	NULL
the	NULL
p75TNF-R	NULL
in	NULL
delivering	NULL
TNF-dependent	NULL
signals	NULL
in	NULL
vivo	NULL
(	NULL
2	NULL
,	NULL
18	NULL
)	NULL
.	NULL

This	NULL
may	NULL
reflect	NULL
either	NULL
a	NULL
well-docu-mented	NULL
preference	NULL
of	NULL
the	NULL
p75TNF-R	NULL
to	NULL
signal	NULL
upon	NULL
bind	NULL
1343	NULL
transgenic	NULL
model	NULL
*	NULL
sepsis	NULL
*	NULL
ligand-	NULL
independent	NULL
signaling	NULL
«	NULL
NF-KB	NULL
activation	NULL
ing	NULL
to	NULL
transmembrane	NULL
(	NULL
19	NULL
)	NULL
rather	NULL
than	NULL
soluble	NULL
TNF	NULL
(	NULL
20	NULL
)	NULL
,	NULL
or	NULL
an	NULL
apparently	NULL
essential	NULL
requirement	NULL
for	NULL
this	NULL
receptor	NULL
to	NULL
reach	NULL
an	NULL
induced	NULL
density	NULL
state	NULL
in	NULL
order	NULL
to	NULL
transmit	NULL
an	NULL
independent	NULL
biological	NULL
signal	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
a	NULL
most	NULL
important	NULL
feature	NULL
of	NULL
the	NULL
p75TNF-R	NULL
,	NULL
which	NULL
distinguishes	NULL
it	NULL
from	NULL
the	NULL
p55TNF-R	NULL
,	NULL
has	NULL
been	NULL
its	NULL
highly	NULL
inducible	NULL
production	NULL
mainly	NULL
on	NULL
cells	NULL
of	NULL
hematopoietic	NULL
origin	NULL
(	NULL
2	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
chronic	NULL
enhanced	NULL
production	NULL
of	NULL
the	NULL
soluble	NULL
p75TNF-R	NULL
demarcates	NULL
many	NULL
fatal	NULL
human	NULL
inflammatory	NULL
and	NULL
autoimmune	NULL
conditions	NULL
,	NULL
including	NULL
sepsis	NULL
(	NULL
24	NULL
)	NULL
,	NULL
chronic	NULL
viral	NULL
hepatic	NULL
disease	NULL
(	NULL
25	NULL
)	NULL
,	NULL
acute	NULL
respiratory	NULL
distress	NULL
syndrome	NULL
(	NULL
26	NULL
)	NULL
,	NULL
acute	NULL
pancreatitis	NULL
(	NULL
27	NULL
)	NULL
,	NULL
lupus	NULL
(	NULL
28	NULL
)	NULL
,	NULL
rheumatoid	NULL
arthritis	NULL
(	NULL
29	NULL
)	NULL
,	NULL
and	NULL
AIDS	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Perhaps	NULL
most	NULL
importantly	NULL
,	NULL
sustained	NULL
production	NULL
of	NULL
the	NULL
p75TNF-R	NULL
during	NULL
disease	NULL
is	NULL
rarely	NULL
accompanied	NULL
by	NULL
chronically	NULL
elevated	NULL
levels	NULL
of	NULL
TNF	NULL
indicating	NULL
a	NULL
regulatory	NULL
and	NULL
functional	NULL
disengagement	NULL
from	NULL
TNF	NULL
(	NULL
31	NULL
)	NULL
.	NULL

However	NULL
,	NULL
an	NULL
independent	NULL
role	NULL
for	NULL
this	NULL
receptor	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
inflammatory	NULL
disease	NULL
has	NULL
never	NULL
been	NULL
sug-gested	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
independent	NULL
in	NULL
vivo	NULL
activities	NULL
of	NULL
the	NULL
p75TNF-R	NULL
we	NULL
have	NULL
generated	NULL
and	NULL
studied	NULL
transgenic	NULL
mice	NULL
expressing	NULL
constitutively	NULL
enhanced	NULL
,	NULL
yet	NULL
disease	NULL
relevant	NULL
levels	NULL
of	NULL
a	NULL
wild-type	NULL
human	NULL
p75TNF-R	NULL
.	NULL

Our	NULL
studies	NULL
demonstrate	NULL
that	NULL
this	NULL
receptor	NULL
is	NULL
capable	NULL
of	NULL
inducing	NULL
a	NULL
severe	NULL
multi-organ	NULL
inflammatory	NULL
syndrome	NULL
,	NULL
affecting	NULL
mainly	NULL
the	NULL
liver	NULL
,	NULL
pancreas	NULL
,	NULL
kidney	NULL
,	NULL
and	NULL
lung	NULL
.	NULL

Similarly	NULL
to	NULL
the	NULL
prolonged	NULL
NF-KB	NULL
activation	NULL
observed	NULL
in	NULL
PBMC	NULL
from	NULL
human	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
R	NULL
ockefeller	NULL
University	NULL
Press	NULL
»	NULL
0022-1007/	NULL
98/	NULL
10/	NULL
1343/	NULL
10	NULL
$	NULL
2.00	NULL
Volume	NULL
188	NULL
,	NULL
Number	NULL
7	NULL
,	NULL
October	NULL
5	NULL
,	NULL
1998	NULL
1343-1352	NULL
http	NULL
:	NULL
//	NULL
www.jem.org	NULL
septic	NULL
patients	NULL
and	NULL
shown	NULL
to	NULL
cause	NULL
pathology	NULL
in	NULL
models	NULL
of	NULL
endotoxemia	NULL
(	NULL
32	NULL
)	NULL
,	NULL
NF-kB	NULL
binding	NULL
activity	NULL
is	NULL
found	NULL
constitutively	NULL
increased	NULL
in	NULL
PBMC	NULL
from	NULL
hup75TNF-R	NULL
transgenic	NULL
mice	NULL
suggesting	NULL
an	NULL
in	NULL
vivo	NULL
role	NULL
for	NULL
the	NULL
p75TNF-R	NULL
in	NULL
triggering	NULL
this	NULL
pathogenic	NULL
cascade	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
severity	NULL
of	NULL
pathology	NULL
developing	NULL
in	NULL
the	NULL
human	NULL
p75TNF-R	NULL
transgenic	NULL
mice	NULL
was	NULL
analogous	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
soluble	NULL
p75TNF-R	NULL
measured	NULL
in	NULL
the	NULL
sera	NULL
of	NULL
these	NULL
animals	NULL
,	NULL
simulating	NULL
the	NULL
quantitative	NULL
correlation	NULL
between	NULL
levels	NULL
of	NULL
human	NULL
soluble	NULL
p75TNF-R	NULL
production	NULL
and	NULL
severity	NULL
of	NULL
human	NULL
disease	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Remarkably	NULL
,	NULL
the	NULL
pathogenic	NULL
potential	NULL
of	NULL
this	NULL
receptor	NULL
is	NULL
shown	NULL
here	NULL
to	NULL
be	NULL
exerted	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
its	NULL
known	NULL
ligands	NULL
,	NULL
TNF	NULL
or	NULL
lymphotoxin	NULL
«	NULL
(	NULL
LT	NULL
a	NULL
)	NULL
,	NULL
``	NULL
and	NULL
independently	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
pSSTNF-R	NULL
.	NULL

These	NULL
results	NULL
establish	NULL
an	NULL
independent	NULL
role	NULL
for	NULL
induced	NULL
production	NULL
of	NULL
the	NULL
p75TNF-R	NULL
in	NULL
inflammatory	NULL
disease	NULL
pathogenesis	NULL
and	NULL
suggest	NULL
that	NULL
antagonistic	NULL
intervention	NULL
with	NULL
the	NULL
functioning	NULL
of	NULL
this	NULL
receptor	NULL
may	NULL
potentially	NULL
be	NULL
beneficial	NULL
in	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
associated	NULL
human	NULL
pathologies	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Transgenic	NULL
and	NULL
Knodkout	NULL
Mice	NULL
.	NULL

The	NULL
hup75TNF-R	NULL
gene	NULL
was	NULL
isolated	NULL
from	NULL
a	NULL
human	NULL
genomic	NULL
P1l-bacteriophage	NULL
library	NULL
by	NULL
PCR	NULL
screening	NULL
(	NULL
Genome	NULL
Systems	NULL
Inc.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
using	NULL
the	NULL
primers	NULL
5	NULL
!	NULL

-CAT	NULL
CCC	NULL
TGG	NULL
GAA	NULL
TGC-3	NULL
'	NULL
and	NULL
5-GAA	NULL
GAG	NULL
CGA	NULL
AGT	NULL
CGC-3	NULL
'	NULL
that	NULL
amplify	NULL
a	NULL
214-bp	NULL
region	NULL
of	NULL
hup75TNF-R	NULL
cDNA	NULL
.	NULL

A	NULL
Sall-NotI	NULL
fragment	NULL
of	NULL
~70	NULL
kb	NULL
containing	NULL
both	NULL
5	NULL
and	NULL
3	NULL
'	NULL
sequences	NULL
from	NULL
the	NULL
hup75TNF-R	NULL
cDNA	NULL
was	NULL
prepared	NULL
by	NULL
centrifugation	NULL
on	NULL
a	NULL
5-25	NULL
%	NULL
(	NULL
wt/	NULL
vol	NULL
)	NULL
NaCI	NULL
gradient	NULL
and	NULL
microinjected	NULL
into	NULL
CBA/C57BL/6J	NULL
fertilized	NULL
eggs	NULL
,	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
34	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
transgenic	NULL
founder	NULL
mice	NULL
,	NULL
DNA	NULL
was	NULL
isolated	NULL
from	NULL
tail	NULL
biopsies	NULL
,	NULL
digested	NULL
with	NULL
Sac	NULL
I	NULL
,	NULL
and	NULL
hybridized	NULL
with	NULL
a	NULL
640-bp	NULL
Xhol-	NULL
Bglll	NULL
fragment	NULL
of	NULL
hup75	NULL
cDN	NULL
A.	NULL
Transgenic	NULL
proge-nies	NULL
were	NULL
identified	NULL
by	NULL
Southern	NULL
and	NULL
slot	NULL
blot	NULL
hybridization	NULL
analysis	NULL
.	NULL

TNF	NULL
(	NULL
6	NULL
)	NULL
,	NULL
LTa	NULL
(	NULL
35	NULL
;	NULL
The	NULL
Jackson	NULL
Laboratory	NULL
,	NULL
Bar	NULL
Harbor	NULL
,	NULL
ME	NULL
)	NULL
,	NULL
p55TNF-R	NULL
(	NULL
9	NULL
;	NULL
provided	NULL
by	NULL
Dr.	NULL
Bluethmann	NULL
,	NULL
Hoffman-La	NULL
R	NULL
oche	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
or	NULL
p75TNF-R	NULL
(	NULL
18	NULL
;	NULL
provided	NULL
by	NULL
Dr.	NULL
Moore	NULL
,	NULL
Genentech	NULL
Inc.	NULL
,	NULL
South	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
knockout	NULL
mice	NULL
were	NULL
maintained	NULL
on	NULL
a	NULL
mixed	NULL
1298v	NULL
X	NULL
C57BI/	NULL
6	NULL
genetic	NULL
background	NULL
in	NULL
the	NULL
animal	NULL
facilities	NULL
of	NULL
the	NULL
Hellenic	NULL
Pasteur	NULL
Institute	NULL
.	NULL

RNA	NULL
Preparation	NULL
and	NULL
Analysis	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
freshly	NULL
dissected	NULL
mouse	NULL
tissues	NULL
and	NULL
S1	NULL
nuclease	NULL
protection	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
36	NULL
)	NULL
by	NULL
hybridizing	NULL
25	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
to	NULL
a	NULL
3-kb	NULL
5'-P-end-labeled	NULL
BgllI	NULL
probe	NULL
derived	NULL
from	NULL
the	NULL
5'-end	NULL
of	NULL
the	NULL
hup75TNF-R	NULL
cDNA	NULL
plus	NULL
vector	NULL
se-quences	NULL
.	NULL

Correct	NULL
initiation	NULL
of	NULL
transcription	NULL
from	NULL
the	NULL
hup75TNF-R	NULL
gene	NULL
produces	NULL
a	NULL
mRNA	NULL
that	NULL
protects	NULL
590	NULL
nt	NULL
of	NULL
the	NULL
probe	NULL
from	NULL
S1	NULL
digestion	NULL
.	NULL

Endogenous	NULL
mouse	NULL
p75TNF-R	NULL
expression	NULL
was	NULL
monitored	NULL
by	NULL
a	NULL
3.7	NULL
kb	NULL
5'-*P-end-labeled	NULL
Bglll	NULL
probe	NULL
derived	NULL
from	NULL
the	NULL
5'-end	NULL
of	NULL
mup75TNF-R	NULL
cDNA	NULL
plus	NULL
vector	NULL
sequences	NULL
(	NULL
protected	NULL
fragment	NULL
137	NULL
bp	NULL
)	NULL
.	NULL

A	NULL
5'-end-labeled	NULL
B-actin	NULL
DNA	NULL
probe	NULL
(	NULL
protected	NULL
fragment	NULL
110	NULL
bp	NULL
)	NULL
was	NULL
used	NULL
to	NULL
control	NULL
for	NULL
quantitative	NULL
differences	NULL
between	NULL
RN	NULL
A	NULL
preparations	NULL
.	NULL

Thymocyte	NULL
Proliferation	NULL
Assay	NULL
.	NULL

_	NULL
Freshly	NULL
isolated	NULL
murine	NULL
thymocytes	NULL
from	NULL
5-wk-old	NULL
mice	NULL
were	NULL
cultured	NULL
in	NULL
96-well	NULL
flat-bot-tomed	NULL
culture	NULL
plates	NULL
(	NULL
6	NULL
X	NULL
10°/0.1	NULL
ml	NULL
;	NULL
Costar	NULL
Corp.	NULL
,	NULL
Cambridge	NULL
,	NULL
'	NULL
A	NULL
bbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
DAB	NULL
,	NULL
diaminobenzidine	NULL
;	NULL
DTT	NULL
,	NULL
dithio-threitol	NULL
;	NULL
LT	NULL
a	NULL
,	NULL
lymphotoxin	NULL
«	NULL
.	NULL

1344	NULL
MA	NULL
)	NULL
in	NULL
DMEM	NULL
medium	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
FCS	NULL
(	NULL
Globe-pharm	NULL
Ltd	NULL
,	NULL
Esher	NULL
,	NULL
UK	NULL
)	NULL
,	NULL
L-glutamine	NULL
,	NULL
penicillin	NULL
,	NULL
streptomycin	NULL
,	NULL
nonessential	NULL
amino	NULL
acids	NULL
(	NULL
GIBCO	NULL
BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
2-mercapto-ethanol	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
La	NULL
Verpilliere	NULL
,	NULL
France	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
pg/ml	NULL
Con	NULL
A	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Human	NULL
rTNF	NULL
(	NULL
specific	NULL
activity	NULL
6	NULL
X	NULL
10	NULL
``	NULL
U/mg	NULL
)	NULL
was	NULL
provided	NULL
by	NULL
the	NULL
Genentech	NULL
manufacturing	NULL
group	NULL
(	NULL
Genentech	NULL
Inc.	NULL
,	NULL
South	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Con	NULL
A	NULL
and	NULL
human	NULL
rTNF	NULL
were	NULL
added	NULL
to	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
0.2	NULL
ml	NULL
.	NULL

After	NULL
60	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
cultures	NULL
were	NULL
pulsed	NULL
with	NULL
1	NULL
mCi	NULL
of	NULL
PH	NULL
thymidine	NULL
(	NULL
25	NULL
Ci/	NULL
mmol	NULL
,	NULL
1	NULL
mCi	NULL
=	NULL
37	NULL
MBq	NULL
;	NULL
Amersham	NULL
Life	NULL
Science	NULL
Ltd	NULL
,	NULL
Little	NULL
Chalfont	NULL
,	NULL
UK	NULL
)	NULL
for	NULL
18	NULL
h	NULL
and	NULL
harvested	NULL
onto	NULL
glass	NULL
fiber	NULL
filters	NULL
(	NULL
Skatron	NULL
Instruments	NULL
,	NULL
Lier	NULL
,	NULL
Norway	NULL
)	NULL
.	NULL

[	NULL
PH	NULL
Jthymidine	NULL
incorporation	NULL
(	NULL
cpm	NULL
)	NULL
of	NULL
triplicate	NULL
cultures	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
liquid	NULL
scintillation	NULL
counter	NULL
(	NULL
LKB	NULL
Wallac	NULL
,	NULL
Turku	NULL
,	NULL
Finland	NULL
)	NULL
.	NULL

TNF	NULL
and	NULL
LPS	NULL
Administration	NULL
.	NULL

-	NULL
Recombinant	NULL
human	NULL
TNF	NULL
(	NULL
Genentech	NULL
Inc.	NULL
)	NULL
was	NULL
administered	NULL
intravenously	NULL
at	NULL
60-150	NULL
g/	NULL
mouse	NULL
in	NULL
0.2	NULL
ml	NULL
of	NULL
PBS	NULL
.	NULL

Susceptibility	NULL
to	NULL
LPS	NULL
was	NULL
assessed	NULL
by	NULL
injecting	NULL
mice	NULL
(	NULL
10-12	NULL
wk	NULL
of	NULL
age	NULL
)	NULL
intraperitoneally	NULL
with	NULL
200-1,200	NULL
wg/25	NULL
g	NULL
of	NULL
body	NULL
weight	NULL
with	NULL
LPS	NULL
(	NULL
Salmonella	NULL
enteritis	NULL
,	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
in	NULL
0.2	NULL
ml	NULL
saline	NULL
.	NULL

Control	NULL
and	NULL
transgenic	NULL
mice	NULL
are	NULL
littermates	NULL
.	NULL

Lethality	NULL
was	NULL
monitored	NULL
for	NULL
5	NULL
d	NULL
and	NULL
indicated	NULL
as	NULL
le-thality/	NULL
total	NULL
injected	NULL
mice	NULL
.	NULL

Flow	NULL
Cytometry	NULL
.	NULL

-	NULL
Freshly	NULL
isolated	NULL
murine	NULL
thymocytes	NULL
were	NULL
adjusted	NULL
to	NULL
2	NULL
X	NULL
10°	NULL
cellyml	NULL
in	NULL
DMEM	NULL
(	NULL
GIBCO	NULL
BRL	NULL
)	NULL
supplemented	NULL
as	NULL
described	NULL
above	NULL
and	NULL
activated	NULL
with	NULL
1	NULL
pg/ml	NULL
Con-canavalin	NULL
A	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Whole	NULL
blood	NULL
was	NULL
collected	NULL
in	NULL
heparinized	NULL
tubes	NULL
followed	NULL
by	NULL
erythrocyte	NULL
depletion	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
expression	NULL
of	NULL
murine	NULL
or	NULL
human	NULL
p75TNF-R	NULL
on	NULL
thymocytes	NULL
or	NULL
whole	NULL
blood	NULL
cells	NULL
,	NULL
10°	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
a	NULL
specific	NULL
anti-mup75TNF-R	NULL
antibody	NULL
(	NULL
rabbit	NULL
polyclonal	NULL
biotin-conjugated	NULL
1:600	NULL
,	NULL
provided	NULL
by	NULL
Dr.	NULL
Wim	NULL
Buurman	NULL
,	NULL
University	NULL
of	NULL
Limburg	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
or	NULL
a	NULL
specific	NULL
anti-hup75TNF-R	NULL
antibody	NULL
(	NULL
M80	NULL
,	NULL
rabbit	NULL
polyclonal	NULL
1:500	NULL
,	NULL
provided	NULL
by	NULL
Dr.	NULL
Matthias	NULL
Grell	NULL
,	NULL
University	NULL
of	NULL
Stuttgart	NULL
;	NULL
reference	NULL
37	NULL
)	NULL
in	NULL
100	NULL
wl	NULL
PBA	NULL
(	NULL
0.1	NULL
%	NULL
BSA	NULL
,	NULL
0.01	NULL
%	NULL
sodium	NULL
azide	NULL
in	NULL
PBS	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

After	NULL
two	NULL
washes	NULL
with	NULL
PBS	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
either	NULL
by	NULL
streptavidine-phycoerythrine	NULL
(	NULL
1:1,000	NULL
;	NULL
PharMingen	NULL
,	NULL
San	NULL
Di-ego	NULL
,	NULL
CA	NULL
)	NULL
to	NULL
detect	NULL
mup75TNF-R	NULL
or	NULL
phycoerythrine-conjugated	NULL
anti-rabbit	NULL
IgG	NULL
(	NULL
1:100	NULL
;	NULL
Vector	NULL
Laboratories	NULL
,	NULL
Inc.	NULL
,	NULL
Burlingame	NULL
,	NULL
CA	NULL
)	NULL
to	NULL
detect	NULL
hup75TNF-R	NULL
.	NULL

Cells	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
Becton	NULL
Dickinson	NULL
Calibur	NULL
flow	NULL
cytometer	NULL
,	NULL
using	NULL
the	NULL
CellQuest	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
&	NULL
Co.	NULL
,	NULL
Sparks	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

ELISA	NULL
for	NULL
Murine	NULL
and	NULL
Human	NULL
p75TNF-R.	NULL
Serum	NULL
was	NULL
collected	NULL
6	NULL
h	NULL
after	NULL
intraperitoneally	NULL
injections	NULL
of	NULL
100	NULL
ug	NULL
LPS	NULL
(	NULL
Salmonella	NULL
enteritis	NULL
,	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

The	NULL
ELISA	NULL
assays	NULL
for	NULL
murine	NULL
and	NULL
human	NULL
p75TNF-Rs	NULL
were	NULL
provided	NULL
by	NULL
Dr.	NULL
Wim	NULL
Buurman	NULL
and	NULL
performed	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
38	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
96-well	NULL
Im-muno-Maxisorp	NULL
Plates	NULL
(	NULL
Nunc	NULL
,	NULL
Roskilde	NULL
,	NULL
Denmark	NULL
)	NULL
were	NULL
coated	NULL
overnight	NULL
at	NULL
4°C	NULL
with	NULL
polyclonal	NULL
antibodies	NULL
specific	NULL
for	NULL
either	NULL
receptor	NULL
.	NULL

Sera	NULL
and	NULL
standard	NULL
titration	NULL
samples	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Subsequently	NULL
,	NULL
plates	NULL
were	NULL
incubated	NULL
with	NULL
biotin-labeled	NULL
rabbit	NULL
polyclonal	NULL
anti-murine	NULL
or	NULL
anti-human	NULL
p75TNF-R	NULL
antibodies	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
final	NULL
incubation	NULL
with	NULL
Horseradish	NULL
Peroxidase	NULL
Streptavidin	NULL
(	NULL
Vector	NULL
Laboratories	NULL
Inc.	NULL
)	NULL
.	NULL

ELISA	NULL
was	NULL
developed	NULL
with	NULL
100	NULL
pul	NULL
of	NULL
0.5	NULL
mg/ml	NULL
O-phe-nyldiamine	NULL
dihydrochloride	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
containing	NULL
0.03	NULL
%	NULL
H	NULL
;	NULL
,0	NULL
»	NULL
;	NULL
,	NULL
and	NULL
the	NULL
reaction	NULL
was	NULL
terminated	NULL
with	NULL
50	NULL
pul	NULL
of	NULL
2	NULL
nM	NULL
H	NULL
,	NULL
SO	NULL
,	NULL
.	NULL

ODjy	NULL
,	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
MRX	NULL
microplate	NULL
Reader	NULL
(	NULL
Dynatech	NULL
,	NULL
Chantilly	NULL
,	NULL
VA	NULL
)	NULL
.	NULL

Histopathology	NULL
and	NULL
Immunocytochemistry	NULL
.	NULL

Tissues	NULL
from	NULL
freshly	NULL
dissected	NULL
mice	NULL
were	NULL
immersion-fixed	NULL
overnight	NULL
in	NULL
neutral	NULL
buff	NULL
ered	NULL
formalin	NULL
and	NULL
embedded	NULL
in	NULL
paraplast	NULL
(	NULL
BDH	NULL
Laboratory	NULL
Sup-plies	NULL
,	NULL
Dorset	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

Sections	NULL
were	NULL
cut	NULL
and	NULL
stained	NULL
with	NULL
hematoxy-	NULL
Multi-	NULL
Organ	NULL
Inflammation	NULL
by	NULL
Increased	NULL
Expression	NULL
of	NULL
the	NULL
D75STNF-R	NULL
lin	NULL
and	NULL
eosin	NULL
according	NULL
to	NULL
standard	NULL
procedures	NULL
,	NULL
dehydrated	NULL
and	NULL
mounted	NULL
in	NULL
DPX	NULL
(	NULL
BDH	NULL
Laboratory	NULL
Supplies	NULL
)	NULL
.	NULL

Immunocytochemical	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
splenic	NULL
cryo-stat	NULL
sections	NULL
.	NULL

Immediately	NULL
before	NULL
use	NULL
,	NULL
sections	NULL
were	NULL
fixed	NULL
for	NULL
10	NULL
min	NULL
in	NULL
acetone	NULL
containing	NULL
0.03	NULL
%	NULL
H	NULL
,	NULL
O	NULL
;	NULL
to	NULL
block	NULL
endogenous	NULL
peroxidase	NULL
activity	NULL
.	NULL

For	NULL
double	NULL
immunostaining	NULL
for	NULL
IgM	NULL
and	NULL
CD3	NULL
,	NULL
sections	NULL
were	NULL
rehydrated	NULL
in	NULL
PBS	NULL
and	NULL
incubated	NULL
with	NULL
per-oxidase-labeled	NULL
goat	NULL
anti-mouse	NULL
IgM	NULL
Ab	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
and	NULL
rat	NULL
anti-mouse	NULL
CD3	NULL
mAb	NULL
(	NULL
clone	NULL
KT	NULL
[	NULL
39	NULL
]	NULL
provided	NULL
by	NULL
Dr.	NULL
S.	NULL
Cobbold	NULL
,	NULL
Sir	NULL
William	NULL
Dunn	NULL
School	NULL
of	NULL
Pathology	NULL
,	NULL
Oxford	NULL
,	NULL
UK	NULL
)	NULL
for	NULL
3	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Subsequently	NULL
,	NULL
sections	NULL
were	NULL
incubated	NULL
with	NULL
biotin-conjugated	NULL
anti-rat	NULL
IgG	NULL
antibody	NULL
(	NULL
Southern	NULL
Biotechnology	NULL
Associates	NULL
Inc.	NULL
,	NULL
Birmingham	NULL
,	NULL
AL	NULL
)	NULL
followed	NULL
by	NULL
streptavidin-alkaline	NULL
phosphatase	NULL
(	NULL
Vector	NULL
Laboratories	NULL
)	NULL
.	NULL

Bound	NULL
peroxidase	NULL
activity	NULL
was	NULL
detected	NULL
by	NULL
staining	NULL
with	NULL
diaminobenzi-dine	NULL
(	NULL
DAB	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
,	NULL
and	NULL
alkaline	NULL
phosphatase	NULL
activity	NULL
was	NULL
visualized	NULL
with	NULL
Fast	NULL
Blue	NULL
BB	NULL
Base	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Nudear	NULL
Extrad¢	NULL
Preparation	NULL
and	NULL
Eledrophoretic	NULL
Mobility	NULL
Shift	NULL
As-says	NULL
.	NULL

-	NULL
Blood	NULL
was	NULL
collected	NULL
by	NULL
cardiac	NULL
puncture	NULL
in	NULL
heparinized	NULL
tubes	NULL
and	NULL
PBMC	NULL
were	NULL
isolated	NULL
by	NULL
centrifugation	NULL
on	NULL
Histopaque-1077	NULL
gradient	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
mononuclear	NULL
band	NULL
was	NULL
aspirated	NULL
,	NULL
washed	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
analyzed	NULL
microscopically	NULL
.	NULL

Nuclear	NULL
proteins	NULL
were	NULL
harvested	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
(	NULL
40	NULL
)	NULL
.	NULL

2	NULL
X	NULL
10°	NULL
PBMC	NULL
were	NULL
lysed	NULL
in	NULL
1	NULL
vol	NULL
of	NULL
cold	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
1.5	NULL
mM	NULL
MgC	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
10	NULL
g/	NULL
ml	NULL
aprotinin	NULL
,	NULL
10	NULL
pg/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
10	NULL
g/	NULL
ml	NULL
type	NULL
I-S	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
)	NULL
,	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
and	NULL
centrifuged	NULL
in	NULL
an	NULL
Eppendorf	NULL
microcentrifuge	NULL
for	NULL
20	NULL
s	NULL
at	NULL
highest	NULL
speed	NULL
.	NULL

The	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
2/3	NULL
vol	NULL
of	NULL
cold	NULL
buffer	NULL
C	NULL
(	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
420	NULL
mM	NULL
NaCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
10	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
10	NULL
jug/	NULL
ml	NULL
leupeptin	NULL
,	NULL
and	NULL
10	NULL
g/ml	NULL
type	NULL
I-S	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
)	NULL
,	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
centrifuged	NULL
for	NULL
5	NULL
min	NULL
,	NULL
4°C	NULL
,	NULL
at	NULL
highest	NULL
speed	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
quick	NULL
frozen	NULL
at	NULL
-80°C	NULL
.	NULL

Total	NULL
protein	NULL
concentration	NULL
was	NULL
determined	NULL
according	NULL
to	NULL
the	NULL
Bradford	NULL
method	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
incubating	NULL
10	NULL
pug	NULL
of	NULL
nuclear	NULL
extract	NULL
with	NULL
4	NULL
jg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
in	NULL
a	NULL
binding	NULL
buffer	NULL
(	NULL
5	NULL
nM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
5	NULL
nM	NULL
MgC	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
)	NULL
,	NULL
at	NULL
20	NULL
pl	NULL
final	NULL
volume	NULL
,	NULL
for	NULL
20	NULL
min	NULL
at	NULL
RT	NULL
.	NULL

An	NULL
end-labeled	NULL
,	NULL
double-stranded	NULL
,	NULL
NF-rB-specific	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
MWG-Biotech	NULL
,	NULL
Ebers	NULL
berg	NULL
,	NULL
Germany	NULL
)	NULL
containing	NULL
the	NULL
two	NULL
tandemly	NULL
arranged	NULL
NF-KB	NULL
binding	NULL
sites	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
5-ATC	NULL
AGG	NULL
GAC	NULL
TTT	NULL
CCGCTG	NULL
GGG	NULL
ACT	NULL
TTC	NULL
CG-3	NULL
'	NULL
)	NULL
was	NULL
used	NULL
to	NULL
assay	NULL
for	NULL
NF-kB	NULL
binding	NULL
activity	NULL
(	NULL
10	NULL
)	NULL
,	NULL
whereas	NULL
an	NULL
end-labeled	NULL
double-stranded	NULL
OCT	NULL
1-specific	NULL
oligonucleotide	NULL
probe	NULL
5-TGT	NULL
CGA	NULL
ATG	NULL
CAA	NULL
ATC	NULL
ACT	NULL
AGA	NULL
A-3	NULL
'	NULL
(	NULL
MWG-Biotech	NULL
)	NULL
was	NULL
used	NULL
as	NULL
an	NULL
internal	NULL
quantitative	NULL
control	NULL
.	NULL

Specificity	NULL
of	NULL
binding	NULL
was	NULL
ascertained	NULL
by	NULL
competition	NULL
with	NULL
a	NULL
150-fold	NULL
molar	NULL
excess	NULL
of	NULL
cold	NULL
consensus	NULL
NF-KB	NULL
or	NULL
OCT	NULL
1	NULL
oligonucle-otides	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
the	NULL
free	NULL
DNA	NULL
probe	NULL
by	NULL
electrophoresis	NULL
through	NULL
6	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Results	NULL
Transgene	NULL
Expression	NULL
Pattems	NULL
and	NULL
Protein	NULL
Production	NULL
in	NULL
Human	NULL
p75TNF-R	NULL
Transgenic	NULL
Mice	NULL
.	NULL

The	NULL
hup75TNF-R	NULL
gene	NULL
was	NULL
isolated	NULL
from	NULL
a	NULL
human	NULL
genomic	NULL
P1-bacteriophage	NULL
library	NULL
by	NULL
PCR	NULL
screening	NULL
(	NULL
Genome	NULL
Systems	NULL
Inc.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

1345	NULL
Douni	NULL
and	NULL
Kollias	NULL
A	NULL
large	NULL
Sall-NotI	NULL
insert	NULL
of	NULL
~70	NULL
kb	NULL
,	NULL
was	NULL
found	NULL
to	NULL
contain	NULL
both	NULL
5	NULL
'	NULL
and	NULL
3	NULL
``	NULL
sequences	NULL
from	NULL
the	NULL
hup75TNF-R	NULL
cDNA	NULL
and	NULL
was	NULL
used	NULL
for	NULL
transgenesis	NULL
.	NULL

Three	NULL
transgenic	NULL
lines	NULL
were	NULL
generated	NULL
(	NULL
TgE1322	NULL
,	NULL
TgE1334	NULL
,	NULL
and	NULL
TgE1335	NULL
)	NULL
carrying	NULL
various	NULL
transgene	NULL
copy	NULL
numbers	NULL
.	NULL

The	NULL
integrity	NULL
of	NULL
the	NULL
inserted	NULL
DNA	NULL
was	NULL
confirmed	NULL
by	NULL
Southern	NULL
hybridization	NULL
analysis	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
whether	NULL
regulation	NULL
and	NULL
tissue	NULL
patterns	NULL
of	NULL
transgene	NULL
expression	NULL
were	NULL
physiologically	NULL
rele-vant	NULL
,	NULL
steady	NULL
state	NULL
hup75TNF-R	NULL
mRNA	NULL
levels	NULL
were	NULL
measured	NULL
by	NULL
Sl-nuclease	NULL
protection	NULL
assays	NULL
on	NULL
total	NULL
RNA	NULL
from	NULL
several	NULL
transgenic	NULL
tissues	NULL
Correctly	NULL
initiated	NULL
hup75TNF-R	NULL
-specific	NULL
transcripts	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
several	NULL
tissues	NULL
examined	NULL
from	NULL
transgenic	NULL
mouse	NULL
lines	NULL
TgE1334	NULL
and	NULL
TgE1335	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
or	NULL
TgE1322	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Patterns	NULL
of	NULL
expression	NULL
were	NULL
comparable	NULL
to	NULL
those	NULL
seen	NULL
for	NULL
the	NULL
endogenous	NULL
p75TNF-R	NULL
mRNA	NULL
with	NULL
the	NULL
highest	NULL
levels	NULL
seen	NULL
in	NULL
lymphoid	NULL
tissues	NULL
,	NULL
liver	NULL
,	NULL
and	NULL
lung	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Overall	NULL
levels	NULL
of	NULL
transgene	NULL
expression	NULL
differed	NULL
between	NULL
lines	NULL
and	NULL
were	NULL
dependent	NULL
on	NULL
transgene	NULL
copy	NULL
number	NULL
.	NULL

TgE1334	NULL
mice	NULL
carrying	NULL
low	NULL
transgene	NULL
copy	NULL
numbers	NULL
expressed	NULL
lower	NULL
levels	NULL
of	NULL
human	NULL
p75TNF-R	NULL
compared	NULL
with	NULL
the	NULL
higher	NULL
transgene	NULL
copy	NULL
number	NULL
TgE1335	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
or	NULL
TgE1322	NULL
mice	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
important	NULL
as-acting	NULL
regulatory	NULL
elements	NULL
controlling	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
hup75TNF-R	NULL
gene	NULL
were	NULL
included	NULL
in	NULL
the	NULL
microinjected	NULL
fragment	NULL
and	NULL
that	NULL
correctly	NULL
regulated	NULL
patterns	NULL
of	NULL
transgene	NULL
expression	NULL
could	NULL
be	NULL
established	NULL
in	NULL
these	NULL
transgenic	NULL
mice	NULL
.	NULL

Expression	NULL
of	NULL
cell	NULL
surface	NULL
p75TNF-R	NULL
s	NULL
was	NULL
assessed	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
on	NULL
Con	NULL
A-activated	NULL
transgenic	NULL
thymocytes	NULL
and	NULL
on	NULL
freshly	NULL
isolated	NULL
peripheral	NULL
blood	NULL
cells	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
murine	NULL
p75TNF-R	NULL
on	NULL
normal	NULL
activated	NULL
thymocytes	NULL
,	NULL
induced	NULL
expression	NULL
of	NULL
human	NULL
p75TNF-R	NULL
could	NULL
be	NULL
observed	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
ConA-activated	NULL
transgenic	NULL
thymocytes	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
,	NULL
indicating	NULL
correct	NULL
regulation	NULL
of	NULL
the	NULL
hup75TNF-R	NULL
protein	NULL
production	NULL
.	NULL

Moreover	NULL
,	NULL
transgenic	NULL
PBMC	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
total	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
were	NULL
also	NULL
found	NULL
to	NULL
express	NULL
on	NULL
their	NULL
surface	NULL
the	NULL
human	NULL
p75TNF-R	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
using	NULL
double	NULL
immunostaining	NULL
of	NULL
liver	NULL
sections	NULL
with	NULL
F4/	NULL
80	NULL
and	NULL
anti-p75TNF-R	NULL
antibodies	NULL
,	NULL
the	NULL
kupffer	NULL
cell	NULL
was	NULL
identified	NULL
as	NULL
a	NULL
source	NULL
of	NULL
both	NULL
endogenous	NULL
or	NULL
transgenic	NULL
p75TNF-R	NULL
s	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Serum	NULL
levels	NULL
of	NULL
soluble	NULL
human	NULL
and	NULL
murine	NULL
p75TNF-R	NULL
s	NULL
(	NULL
sp75TNF-R	NULL
)	NULL
were	NULL
measured	NULL
in	NULL
TgE1334	NULL
and	NULL
TgE1335	NULL
transgenic	NULL
mice	NULL
before	NULL
or	NULL
after	NULL
stimulation	NULL
by	NULL
LPS	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Both	NULL
transgenic	NULL
lines	NULL
were	NULL
shown	NULL
to	NULL
produce	NULL
in	NULL
their	NULL
serum	NULL
human	NULL
sp75TNF-R.	NULL
TgE1334	NULL
mice	NULL
produced	NULL
the	NULL
transgenic	NULL
receptor	NULL
at	NULL
levels	NULL
comparable	NULL
to	NULL
the	NULL
endogenous	NULL
sp75TNF-R	NULL
in	NULL
normal	NULL
control	NULL
mice	NULL
(	NULL
~10	NULL
+	NULL
2.5	NULL
ng/	NULL
ml	NULL
for	NULL
either	NULL
receptor	NULL
,	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
whereas	NULL
TgE1335	NULL
mice	NULL
expressed	NULL
an	NULL
overall	NULL
three-	NULL
to	NULL
fourfold	NULL
increased	NULL
levels	NULL
of	NULL
transgenic	NULL
sp75TNF-R	NULL
(	NULL
~33	NULL
+	NULL
4.3	NULL
ng/ml	NULL
of	NULL
transgenic	NULL
versus	NULL
10	NULL
+	NULL
2.5	NULL
ng/	NULL
ml	NULL
of	NULL
the	NULL
endogenous	NULL
in	NULL
normal	NULL
mice	NULL
,	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

After	NULL
challenge	NULL
by	NULL
LPS	NULL
in	NULL
vivo	NULL
,	NULL
human	NULL
and	NULL
murine	NULL
sp75TNF-R	NULL
levels	NULL
were	NULL
comparable	NULL
in	NULL
heterozygous	NULL
TgE1334	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
TgE1335	NULL
mice	NULL
versus	NULL
normal	NULL
control	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
,	NULL
indicating	NULL
correct	NULL
regulation	NULL
by	NULL
LPS	NULL
of	NULL
the	NULL
exogenous	NULL
p75TNF-R	NULL
protein	NULL
production	NULL
NORMAL	NULL
Tg	NULL
E1334	NULL
Tg	NULL
E1335	NULL
nts	NULL
in	NULL
Brai	NULL
Thymus	NULL
Spleen	NULL
Liver	NULL
Lung	NULL
Joints	NULL
Thymus	NULL
Liver	NULL
Kidney	NULL
Thymus	NULL
LN	NULL
Liver	NULL
Kid	NULL
Gut	NULL
Spleen	NULL
hup	NULL
75	NULL
mup75	NULL
B-actin	NULL
and	NULL
shedding	NULL
.	NULL

Interestingly	NULL
,	NULL
nonchallenged	NULL
homozygous	NULL
TgE1335	NULL
mice	NULL
produce	NULL
the	NULL
transgenic	NULL
hup75TNF-R	NULL
protein	NULL
at	NULL
levels	NULL
similar	NULL
to	NULL
those	NULL
seen	NULL
for	NULL
endogenous	NULL
p75TNF-R	NULL
in	NULL
LPS-treated	NULL
normal	NULL
control	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

The	NULL
functional	NULL
integrity	NULL
of	NULL
the	NULL
human	NULL
p75TNF-R	NULL
protein	NULL
was	NULL
assessed	NULL
by	NULL
measuring	NULL
its	NULL
activity	NULL
in	NULL
a	NULL
thymocyte	NULL
proliferation	NULL
assay	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Transgenic	NULL
but	NULL
not	NULL
normal	NULL
control	NULL
thymocytes	NULL
were	NULL
induced	NULL
to	NULL
proliferate	NULL
by	NULL
exogenous	NULL
recombinant	NULL
human	NULL
TNF	NULL
demonstrating	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
functional	NULL
human	NULL
p75TNF-R	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

Taken	NULL
togeth-er	NULL
,	NULL
these	NULL
results	NULL
demonstrate	NULL
that	NULL
correctly	NULL
regulated	NULL
and	NULL
physiologically	NULL
relevant	NULL
expression	NULL
of	NULL
a	NULL
functional	NULL
human	NULL
p75TNF-R	NULL
protein	NULL
was	NULL
established	NULL
in	NULL
these	NULL
transgenic	NULL
mice	NULL
.	NULL

Enhanced	NULL
hup75TNF-R	NULL
Expression	NULL
Sensitizes	NULL
Mice	NULL
to	NULL
the	NULL
In	NULL
Vivo	NULL
Toxidty	NULL
of	NULL
huTNF	NULL
and	NULL
LPS	NULL
.	NULL

-	NULL
Previous	NULL
studies	NULL
in	NULL
p75TNF-R	NULL
knockout	NULL
mice	NULL
have	NULL
indicated	NULL
an	NULL
enhancing	NULL
role	NULL
for	NULL
this	NULL
receptor	NULL
in	NULL
the	NULL
lethal	NULL
toxicity	NULL
of	NULL
LPS	NULL
or	NULL
murine	NULL
TNF	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Additional	NULL
studies	NULL
however	NULL
,	NULL
have	NULL
suggested	NULL
a	NULL
neutralizing	NULL
potential	NULL
of	NULL
enhanced	NULL
levels	NULL
of	NULL
soluble	NULL
TNF-Rs	NULL
in	NULL
models	NULL
of	NULL
endotoxemia	NULL
(	NULL
38	NULL
,	NULL
43	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
whether	NULL
expression	NULL
of	NULL
a	NULL
human	NULL
p75TNF-R	NULL
protein	NULL
would	NULL
render	NULL
mice	NULL
more	NULL
resistant	NULL
or	NULL
more	NULL
susceptible	NULL
to	NULL
LPS	NULL
or	NULL
huTNF	NULL
administration	NULL
,	NULL
and	NULL
to	NULL
determine	NULL
the	NULL
net	NULL
in	NULL
vivo	NULL
effect	NULL
of	NULL
hup75TNF-R	NULL
overexpression	NULL
in	NULL
endotoxemic	NULL
mice	NULL
,	NULL
we	NULL
measured	NULL
lethality	NULL
rates	NULL
in	NULL
Tg1335	NULL
and	NULL
control	NULL
animals	NULL
challenged	NULL
intravenously	NULL
or	NULL
intraperitoneally	NULL
with	NULL
different	NULL
doses	NULL
of	NULL
recombinant	NULL
huTNF	NULL
or	NULL
LPS	NULL
respectively	NULL
.	NULL

Table	NULL
1	NULL
summarizes	NULL
the	NULL
results	NULL
of	NULL
these	NULL
experiments	NULL
.	NULL

Human	NULL
p75TNF-R	NULL
expression	NULL
is	NULL
shown	NULL
to	NULL
potently	NULL
sensitize	NULL
transgenic	NULL
mice	NULL
to	NULL
the	NULL
toxicity	NULL
of	NULL
an	NULL
otherwise	NULL
sublethal	NULL
dose	NULL
of	NULL
either	NULL
rhuTNF	NULL
(	NULL
90	NULL
mg	NULL
)	NULL
or	NULL
LPS	NULL
(	NULL
800	NULL
pg	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
induced	NULL
production	NULL
of	NULL
the	NULL
hup75TNF-R	NULL
protein	NULL
contributes	NULL
positively	NULL
to	NULL
the	NULL
lethal	NULL
outcome	NULL
of	NULL
endotoxemia	NULL
.	NULL

Sustained	NULL
Overproduction	NULL
of	NULL
the	NULL
p75STNF-R	NULL
Triggers	NULL
Multi-organ	NULL
Inflammatory	NULL
Pathology	NULL
.	NULL

Mice	NULL
heterozygous	NULL
for	NULL
the	NULL
hup75TNF-R	NULL
transgene	NULL
from	NULL
all	NULL
three	NULL
transgenic	NULL
lines	NULL
develop	NULL
and	NULL
grow	NULL
normally	NULL
and	NULL
display	NULL
no	NULL
pathological	NULL
changes	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
mice	NULL
from	NULL
the	NULL
highest	NULL
expressing	NULL
line	NULL
TgE1335	NULL
that	NULL
develop	NULL
a	NULL
chronic	NULL
but	NULL
mild	NULL
peri-vascular	NULL
inflammatory	NULL
pathology	NULL
in	NULL
liver	NULL
,	NULL
pancreas	NULL
,	NULL
and	NULL
lung	NULL
at	NULL
2-3	NULL
mo	NULL
of	NULL
age	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
homozygous	NULL
TgE1335	NULL
or	NULL
TgE1322	NULL
mice	NULL
develop	NULL
a	NULL
severe	NULL
pathology	NULL
1346	NULL
rey	NULL
9	NULL
§	NULL
Lung	NULL
Gu	NULL
nts	NULL
in	NULL
Brai	NULL
Joi	NULL
Figure	NULL
1	NULL
.	NULL

S1	NULL
nuclease	NULL
protection	NULL
analysis	NULL
of	NULL
total	NULL
RNA	NULL
from	NULL
tissues	NULL
of	NULL
normal	NULL
,	NULL
TgE1334	NULL
and	NULL
TgE1335	NULL
mice	NULL
shows	NULL
correct	NULL
patterns	NULL
of	NULL
expression	NULL
for	NULL
the	NULL
transgenic	NULL
p75TNF-R	NULL
mRNA	NULL
.	NULL

B-actin	NULL
acts	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
sample	NULL
loading	NULL
.	NULL

characterized	NULL
by	NULL
runting	NULL
,	NULL
lethargy	NULL
,	NULL
and	NULL
abdominal	NULL
distension	NULL
and	NULL
accompanied	NULL
by	NULL
a	NULL
severely	NULL
reduced	NULL
weight	NULL
gain	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
disease	NULL
leads	NULL
to	NULL
the	NULL
premature	NULL
death	NULL
of	NULL
these	NULL
animals	NULL
between	NULL
2	NULL
and	NULL
4	NULL
wk	NULL
of	NULL
age	NULL
.	NULL

At	NULL
necropsy	NULL
of	NULL
20-d-old	NULL
homozygous	NULL
TgE1335	NULL
mice	NULL
,	NULL
thymic	NULL
and	NULL
pancreatic	NULL
atrophy	NULL
,	NULL
splenomegaly	NULL
,	NULL
and	NULL
extensive	NULL
liver	NULL
necrosis	NULL
were	NULL
observed	NULL
.	NULL

Histopathological	NULL
analyses	NULL
revealed	NULL
heavy	NULL
peri-	NULL
vascular	NULL
inflammatory	NULL
lesions	NULL
in	NULL
several	NULL
organs	NULL
such	NULL
as	NULL
pancreas	NULL
,	NULL
liver	NULL
,	NULL
lung	NULL
,	NULL
and	NULL
kidney	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
heavy	NULL
in-flammation	NULL
,	NULL
extensive	NULL
ischemic	NULL
tissue	NULL
necrosis	NULL
could	NULL
be	NULL
observed	NULL
in	NULL
the	NULL
liver	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Other	NULL
organs	NULL
and	NULL
sites	NULL
such	NULL
as	NULL
muscle	NULL
and	NULL
brain	NULL
meninges	NULL
were	NULL
also	NULL
inflammatory	NULL
in	NULL
homozygous	NULL
animals	NULL
.	NULL

Infiltrates	NULL
in	NULL
heterozygous	NULL
TgE1335	NULL
animals	NULL
consisted	NULL
mainly	NULL
of	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
polymorphonuclear	NULL
cells	NULL
as	NULL
assessed	NULL
by	NULL
immunocytochemical	NULL
analysis	NULL
using	NULL
cell-specific	NULL
markers	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
although	NULL
a	NULL
similar	NULL
infiltrate	NULL
was	NULL
present	NULL
in	NULL
the	NULL
heavily	NULL
inflamed	NULL
organs	NULL
of	NULL
2-wk-old	NULL
homozygous	NULL
TgE1335	NULL
mice	NULL
,	NULL
a	NULL
striking	NULL
absence	NULL
of	NULL
B220-positive	NULL
B	NULL
cells	NULL
was	NULL
observed	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

IgM	NULL
*	NULL
B	NULL
cells	NULL
were	NULL
also	NULL
shown	NULL
to	NULL
be	NULL
markedly	NULL
decreased	NULL
in	NULL
sections	NULL
of	NULL
spleens	NULL
from	NULL
homozygous	NULL
TgE1335	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

FACS®-analysis	NULL
performed	NULL
in	NULL
peripheral	NULL
blood	NULL
,	NULL
spleen	NULL
,	NULL
and	NULL
bone	NULL
marrow	NULL
cells	NULL
of	NULL
homozygous	NULL
TgE1335	NULL
mice	NULL
confirmed	NULL
the	NULL
almost	NULL
complete	NULL
absence	NULL
of	NULL
B220+IgM-	NULL
and	NULL
B220+IgM*	NULL
B	NULL
cells	NULL
,	NULL
indicating	NULL
impaired	NULL
B	NULL
cell	NULL
development	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
mature	NULL
CD4¢*	NULL
and	NULL
CD8+	NULL
single	NULL
positive	NULL
as	NULL
well	NULL
as	NULL
Mac1*/Gr1	NULL
*	NULL
cells	NULL
could	NULL
readily	NULL
be	NULL
detected	NULL
in	NULL
both	NULL
the	NULL
inflammatory	NULL
infiltrates	NULL
and	NULL
in	NULL
spleen	NULL
and	NULL
blood	NULL
of	NULL
homoT	NULL
gE1335	NULL
mice	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

p75TN	NULL
F-R	NULL
-induced	NULL
Pathology	NULL
Develops	NULL
Even	NULL
in	NULL
the	NULL
Absence	NULL
of	NULL
TNF	NULL
,	NULL
LT	NULL
a	NULL
orthe	NULL
p5STNF-R.	NULL
To	NULL
examine	NULL
the	NULL
dependency	NULL
of	NULL
the	NULL
observed	NULL
p75TNF-R	NULL
-mediated	NULL
pathology	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
TNF	NULL
or	NULL
LT	NULL
«	NULL
ligands	NULL
,	NULL
and	NULL
to	NULL
evaluate	NULL
the	NULL
contribution	NULL
of	NULL
a	NULL
cooperation	NULL
of	NULL
the	NULL
human	NULL
p75TNF-R	NULL
with	NULL
the	NULL
endogenous	NULL
p75	NULL
or	NULL
pS5TNF-R	NULL
s	NULL
,	NULL
we	NULL
have	NULL
introduced	NULL
the	NULL
hup75TNF-R	NULL
transgene	NULL
,	NULL
as	NULL
a	NULL
homozygous	NULL
trait	NULL
,	NULL
into	NULL
genetic	NULL
backgrounds	NULL
deficient	NULL
in	NULL
either	NULL
TNF	NULL
(	NULL
6	NULL
)	NULL
,	NULL
LT	NULL
a	NULL
(	NULL
35	NULL
)	NULL
,	NULL
the	NULL
p75TNF-R	NULL
(	NULL
18	NULL
)	NULL
,	NULL
or	NULL
the	NULL
pSSTNF-R	NULL
(	NULL
9	NULL
)	NULL
.	NULL

In	NULL
all	NULL
four	NULL
deficient	NULL
backgrounds	NULL
,	NULL
homozygous	NULL
TgE1335	NULL
mice	NULL
developed	NULL
fully	NULL
the	NULL
lethal	NULL
multi-organ	NULL
pathology	NULL
.	NULL

Increased	NULL
levels	NULL
of	NULL
the	NULL
human	NULL
p75TNF-R	NULL
are	NULL
therefore	NULL
sufficient	NULL
to	NULL
induce	NULL
disease	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
p55TNF-R	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Most	NULL
importantly	NULL
,	NULL
the	NULL
pathogenic	NULL
potential	NULL
of	NULL
the	NULL
hu-	NULL
Multi-	NULL
Organ	NULL
Inflammation	NULL
by	NULL
Increased	NULL
Expression	NULL
of	NULL
the	NULL
D75STNF-R	NULL
J	NULL
>	NULL
350	NULL
A	NULL
-	NULL
ConA	NULL
+	NULL
ConA	NULL
p	NULL
___20	NULL
%	NULL
_	NULL
p	NULL
____s	NULL
%	NULL
___	NULL
p75-/-	NULL
Normal	NULL
p75/-	NULL
Normal	NULL
g	NULL
NH	NULL
a	NULL
a	NULL
(	NULL
6	NULL
)	NULL
MAN	NULL
10°	NULL
¥	NULL
wo	NULL
10°	NULL
1010	NULL
10	NULL
102	NULL
10	NULL
``	NULL
10+	NULL
anti-mup75	NULL
>	NULL
-	NULL
ConA	NULL
+	NULL
ConA	NULL
22	NULL
%	NULL
|	NULL
57	NULL
%	NULL
Normal	NULL
Normal	NULL
h	NULL
3	NULL
Tg	NULL
E1335	NULL
§	NULL
3	NULL
Tg	NULL
£1335	NULL
O	NULL
10°	NULL
10	NULL
'	NULL
10	NULL
10	NULL
>	NULL
10410	NULL
``	NULL
10	NULL
)	NULL
10	NULL
10	NULL
``	NULL
10+	NULL
anti-hup75	NULL
>	NULL
B	NULL
18000	NULL
E	NULL
16000	NULL
&	NULL
x3	NULL
14000	NULL
-I	NULL
a	NULL
E	NULL
B	NULL
12000	NULL
a	NULL
e	NULL
g	NULL
10000	NULL
k	NULL
S	NULL
-	NULL
s000	NULL
E	NULL
id	NULL
gq	NULL
-	NULL
s000	NULL
d	NULL
4000	NULL
2000	NULL
:	NULL
t	NULL
10	NULL
'	NULL
102	NULL
huTNF	NULL
(	NULL
ng/m1	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
Production	NULL
of	NULL
a	NULL
functional	NULL
hup75TNF-R	NULL
protein	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
transgenic	NULL
thymocytes	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Freshly	NULL
isolated	NULL
or	NULL
ConA-stimulated	NULL
thymocytes	NULL
from	NULL
normal	NULL
,	NULL
TgE1335	NULL
,	NULL
and	NULL
mup75TNF-R	NULL
knockout	NULL
mice	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
murine	NULL
and	NULL
human	NULL
p75TNF-R	NULL
protein	NULL
.	NULL

Approximately	NULL
20	NULL
and	NULL
22	NULL
%	NULL
of	NULL
freshly	NULL
isolated	NULL
normal	NULL
and	NULL
transgenic	NULL
thymocytes	NULL
were	NULL
found	NULL
to	NULL
express	NULL
endogenous	NULL
or	NULL
transgenic	NULL
p75TNF-R	NULL
,	NULL
respectively	NULL
.	NULL

ConA	NULL
stimulation	NULL
resulted	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
both	NULL
the	NULL
murine	NULL
p75TNF-R	NULL
in	NULL
normal	NULL
mice	NULL
(	NULL
60	NULL
%	NULL
of	NULL
cells	NULL
pos-itive	NULL
)	NULL
and	NULL
the	NULL
human	NULL
p75TNF-R	NULL
in	NULL
transgenic	NULL
mice	NULL
(	NULL
57	NULL
%	NULL
of	NULL
cells	NULL
posi-tive	NULL
)	NULL
.	NULL

Thymocytes	NULL
from	NULL
normal	NULL
or	NULL
p75TNF-R-deficient	NULL
mice	NULL
are	NULL
used	NULL
as	NULL
negative	NULL
controls	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Proliferative	NULL
response	NULL
of	NULL
ConA-treated	NULL
TgE1335	NULL
(	NULL
@	NULL
)	NULL
and	NULL
normal	NULL
(	NULL
O	NULL
)	NULL
thymocytes	NULL
to	NULL
human	NULL
rTNF	NULL
reveals	NULL
a	NULL
functional	NULL
human	NULL
p75TNF-R	NULL
protein	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
°H	NULL
incorporation	NULL
in	NULL
either	NULL
normal	NULL
or	NULL
transgenic	NULL
thymocytes	NULL
treated	NULL
with	NULL
ConA	NULL
alone	NULL
is	NULL
indicated	NULL
by	NULL
a	NULL
dashed	NULL
line	NULL
.	NULL

R	NULL
esults	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

man	NULL
p75TNF-R	NULL
could	NULL
be	NULL
exerted	NULL
independent	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
TNF	NULL
(	NULL
Figs	NULL
.	NULL

4	NULL
and	NULL
5	NULL
)	NULL
or	NULL
LT	NULL
a	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
however	NULL
,	NULL
although	NULL
the	NULL
p55TNF-R	NULL
and	NULL
LTa	NULL
were	NULL
dispensable	NULL
for	NULL
the	NULL
development	NULL
of	NULL
pathology	NULL
,	NULL
a	NULL
low	NULL
but	NULL
1347	NULL
Douni	NULL
and	NULL
Kollias	NULL
200	NULL
-	NULL
mup75	NULL
C	NULL
)	NULL
meses	NULL
hup	NULL
75	NULL
BP	NULL
aso	NULL
{	NULL
ag	NULL
g	NULL
200	NULL
4	NULL
ll	NULL
wn	NULL
150	NULL
1	NULL
a	NULL
:	NULL
2	NULL
&	NULL
100	NULL
a	NULL
C	NULL
9	NULL
so	NULL
o	NULL
LPS	NULL
-	NULL
4+	NULL
-	NULL
4+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-_-Normal	NULL
TgE133Shet	NULL
-	NULL
TgF1335hom	NULL
(	NULL
n=4	NULL
)	NULL
(	NULL
n=4	NULL
)	NULL
(	NULL
n=4	NULL
)	NULL
B	NULL
TgE133Shom	NULL
5	NULL
93	NULL
€	NULL
3	NULL
a	NULL
ic	NULL
&	NULL
C	NULL
10°	NULL
10°	NULL
102	NULL
10	NULL
104	NULL
@	NULL
nti-Rup75	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-	NULL
»	NULL
Figure	NULL
3	NULL
.	NULL

-	NULL
Production	NULL
of	NULL
soluble	NULL
and	NULL
cell	NULL
surface	NULL
hup75TNF-R	NULL
protein	NULL
in	NULL
transgenic	NULL
sera	NULL
and	NULL
on	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Serum	NULL
levels	NULL
of	NULL
soluble	NULL
mup75	NULL
and	NULL
hup75TNF-Rs	NULL
were	NULL
measured	NULL
by	NULL
specific	NULL
ELISAs	NULL
,	NULL
before	NULL
or	NULL
after	NULL
LPS-administration	NULL
in	NULL
normal	NULL
(	NULL
#	NULL
=	NULL
4	NULL
)	NULL
,	NULL
and	NULL
TgB1335	NULL
heterozygous	NULL
(	NULL
7	NULL
=	NULL
4	NULL
)	NULL
mice	NULL
.	NULL

Total	NULL
(	NULL
murine	NULL
and	NULL
human	NULL
)	NULL
sp75TNF-R	NULL
production	NULL
in	NULL
heterozygous	NULL
TgE1335	NULL
mice	NULL
is	NULL
increased	NULL
approximately	NULL
fivefold	NULL
in	NULL
comparison	NULL
to	NULL
the	NULL
production	NULL
of	NULL
endogenous	NULL
sp75TNF-R	NULL
protein	NULL
in	NULL
normal	NULL
mice	NULL
(	NULL
49	NULL
*	NULL
4.5	NULL
ng/ml	NULL
total	NULL
p75TNF-R	NULL
protein	NULL
in	NULL
transgenic	NULL
mice	NULL
versus	NULL
10	NULL
+	NULL
2.5	NULL
ng/ml	NULL
of	NULL
endogenous	NULL
p75TNF-R	NULL
protein	NULL
in	NULL
normal	NULL
mice	NULL
)	NULL
.	NULL

Transgenic	NULL
p75TNF-R	NULL
production	NULL
in	NULL
LPS-treated	NULL
TgB1335	NULL
mice	NULL
is	NULL
regulated	NULL
similarly	NULL
to	NULL
normal	NULL
LPS-treated	NULL
mice	NULL
.	NULL

TgB1335	NULL
homozygous	NULL
mice	NULL
(	NULL
=	NULL
4	NULL
)	NULL
spontaneously	NULL
produce	NULL
highly	NULL
elevated	NULL
levels	NULL
of	NULL
both	NULL
soluble	NULL
murine	NULL
and	NULL
human	NULL
p75TNF-R	NULL
s.	NULL
(	NULL
B	NULL
)	NULL
Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
from	NULL
3-wk-old	NULL
TgE1335	NULL
heterozygous	NULL
or	NULL
homozygous	NULL
mice	NULL
shows	NULL
the	NULL
enhanced	NULL
surface	NULL
expression	NULL
of	NULL
hup75TNF-R	NULL
on	NULL
leukocytes	NULL
taken	NULL
from	NULL
homozygous	NULL
transgenic	NULL
animals	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

measurable	NULL
pathogenic	NULL
contribution	NULL
of	NULL
the	NULL
endogenous	NULL
TNF	NULL
could	NULL
be	NULL
observed	NULL
,	NULL
since	NULL
in	NULL
TNF-deficient	NULL
backgrounds	NULL
homozygous	NULL
TgE1335	NULL
mice	NULL
do	NULL
succumb	NULL
to	NULL
dis	NULL
ease	NULL
but	NULL
with	NULL
a	NULL
delay	NULL
of	NULL
a	NULL
few	NULL
weeks	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

A	NULL
measurable	NULL
delay	NULL
in	NULL
disease	NULL
progression	NULL
was	NULL
also	NULL
evident	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
endogenous	NULL
p75TNF-R	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
especially	NULL
at	NULL
the	NULL
histopathological	NULL
level	NULL
where	NULL
homoTgE1335/	NULL
p75TNF-R	NULL
--	NULL
mice	NULL
displayed	NULL
a	NULL
generally	NULL
milder	NULL
phenotype	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
fewer	NULL
inflammatory	NULL
infiltrates	NULL
in	NULL
several	NULL
organs	NULL
and	NULL
no	NULL
evidence	NULL
for	NULL
necrosis	NULL
in	NULL
liver	NULL
)	NULL
in	NULL
comparison	NULL
to	NULL
homoTgE1335	NULL
controls	NULL
,	NULL
confirming	NULL
that	NULL
development	NULL
of	NULL
pathology	NULL
correlates	NULL
with	NULL
the	NULL
level	NULL
of	NULL
p75TNF-R	NULL
s	NULL
being	NULL
produced	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
enhancing	NULL
pathogenic	NULL
involvement	NULL
of	NULL
endogenous	NULL
TNF	NULL
,	NULL
diseased	NULL
homozygous	NULL
Table	NULL
1	NULL
.	NULL

-	NULL
Human	NULL
p75TNF-R	NULL
Transgenic	NULL
Mice	NULL
Are	NULL
More	NULL
Susceptible	NULL
to	NULL
Lethality	NULL
A	NULL
fter	NULL
A	NULL
dministration	NULL
of	NULL
Human	NULL
rTNF	NULL
or	NULL
LPS	NULL
Dose	NULL
Lethality	NULL
huT	NULL
NF	NULL
(	NULL
g/	NULL
mouse	NULL
)	NULL
LPS	NULL
(	NULL
g/	NULL
25	NULL
g	NULL
)	NULL
_	NULL
Control	NULL
-	NULL
TgB1335	NULL
60	NULL
-	NULL
0/3	NULL
1/3	NULL
90	NULL
-	NULL
1/6	NULL
6/6	NULL
150	NULL
-	NULL
3/3	NULL
3/3	NULL
-	NULL
200	NULL
0/7	NULL
1/7	NULL
-	NULL
400	NULL
0/7	NULL
2/7	NULL
-	NULL
800	NULL
2/7	NULL
7/7	NULL
-	NULL
1200	NULL
5/5	NULL
5/5	NULL
TgE1335	NULL
mice	NULL
show	NULL
dramatically	NULL
increased	NULL
levels	NULL
of	NULL
endogenous	NULL
TNF	NULL
in	NULL
their	NULL
sera	NULL
(	NULL
1.09	NULL
ng/ml	NULL
+1	NULL
0.15	NULL
,	NULL
n	NULL
=	NULL
4	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
a	NULL
similar	NULL
lethal	NULL
multi-organ	NULL
inflammatory	NULL
disease	NULL
could	NULL
be	NULL
triggered	NULL
at	NULL
4-8	NULL
wk	NULL
of	NULL
age	NULL
,	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
pSS5TNF-R	NULL
(	NULL
ie	NULL
.	NULL

,	NULL
in	NULL
a	NULL
pSS5TNF-R	NULL
knockout	NULL
back	NULL
TgE133Shet	NULL
TgE133Shom	NULL
Pancreas	NULL
Liver	NULL
Spleen	NULL
1348	NULL
ground	NULL
)	NULL
,	NULL
in	NULL
heterozygous	NULL
TgE1335	NULL
mice	NULL
bred	NULL
with	NULL
otherwise	NULL
healthy	NULL
transgenic	NULL
mice	NULL
overexpressing	NULL
T	NULL
cell	NULL
targeted	NULL
human	NULL
wild-type	NULL
(	NULL
Tg7	NULL
;	NULL
reference	NULL
15	NULL
)	NULL
,	NULL
or	NULL
transmembrane	NULL
TNF	NULL
(	NULL
Tg5453	NULL
;	NULL
reference	NULL
16	NULL
;	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
result	NULL
shows	NULL
that	NULL
in	NULL
this	NULL
model	NULL
,	NULL
the	NULL
pathogenic	NULL
contribution	NULL
of	NULL
TNF	NULL
results	NULL
from	NULL
direct	NULL
interaction	NULL
with	NULL
the	NULL
p75TNF-R	NULL
and	NULL
does	NULL
not	NULL
necessitate	NULL
a	NULL
functional	NULL
pSSTNF-R	NULL
.	NULL

The	NULL
lethal	NULL
phenotype	NULL
of	NULL
the	NULL
Tg7/TgE1335	NULL
double	NULL
heterozygotes	NULL
,	NULL
but	NULL
not	NULL
the	NULL
baseline	NULL
inflammatory	NULL
complications	NULL
of	NULL
the	NULL
heterozygous	NULL
TgE1335	NULL
line	NULL
could	NULL
be	NULL
completely	NULL
neutralized	NULL
by	NULL
preventive	NULL
treatment	NULL
of	NULL
mice	NULL
with	NULL
a	NULL
specific	NULL
anti-human	NULL
TNF	NULL
antibody	NULL
(	NULL
CBO0ON6	NULL
;	NULL
Celltech	NULL
Therapeutics	NULL
Ltd	NULL
,	NULL
Slough	NULL
,	NULL
UK	NULL
;	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
,	NULL
in	NULL
vivo	NULL
,	NULL
the	NULL
p75TNF-R	NULL
mediates	NULL
inflammatory	NULL
signals	NULL
independently	NULL
of	NULL
the	NULL
presence	NULL
or	NULL
coacti-vation	NULL
of	NULL
the	NULL
pSSTNF-R	NULL
.	NULL

Moreover	NULL
,	NULL
although	NULL
the	NULL
presence	NULL
of	NULL
TNF	NULL
could	NULL
further	NULL
enhance	NULL
the	NULL
spontaneous	NULL
inflammatory	NULL
activities	NULL
of	NULL
the	NULL
p75TNF-R	NULL
,	NULL
its	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
these	NULL
deleterious	NULL
functions	NULL
was	NULL
nonessential	NULL
.	NULL

Enhanced	NULL
NF-kB	NULL
Binding	NULL
Activity	NULL
in	NULL
Nudear	NULL
Extras	NULL
of	NULL
PBMC	NULL
from	NULL
hup75TNF-R	NULL
Transgenic	NULL
Mic	NULL
.	NULL

activation	NULL
is	NULL
believed	NULL
to	NULL
be	NULL
important	NULL
in	NULL
the	NULL
triggering	NULL
of	NULL
proinflammatory	NULL
cytokine	NULL
cascades	NULL
(	NULL
44	NULL
)	NULL
and	NULL
it	NULL
has	NULL
recently	NULL
been	NULL
TgE133Shom	NULL
TNF-/-	NULL
Figure	NULL
__	NULL
4.	NULL
p75TNF-R	NULL
-trig-gered	NULL
multi-organ	NULL
inflammation	NULL
and	NULL
hematopoietic	NULL
abnormalities	NULL
develop	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TNF	NULL
.	NULL

Histopathological	NULL
analysis	NULL
(	NULL
H/E	NULL
)	NULL
in	NULL
liver	NULL
and	NULL
pancreas	NULL
of	NULL
4-mo-old	NULL
heterozygous	NULL
TgE1335	NULL
mice	NULL
(	NULL
TgE1335het	NULL
)	NULL
and	NULL
3-wk-old	NULL
-	NULL
TgE1335	NULL
-	NULL
homozygous	NULL
(	NULL
TgE1335Shom	NULL
)	NULL
or	NULL
homozygous	NULL
TgEB1335	NULL
X	NULL
TNF/~	NULL
_	NULL
mice	NULL
(	NULL
TgE133Shom/TNF'~	NULL
)	NULL
.	NULL

__	NULL
Lesions	NULL
in	NULL
heterozygous	NULL
Tg1335	NULL
mice	NULL
involve	NULL
mainly	NULL
the	NULL
liver	NULL
and	NULL
pancreas	NULL
where	NULL
inflammatory	NULL
infiltrates	NULL
develop	NULL
and	NULL
persist	NULL
chronically	NULL
from	NULL
2-3	NULL
mo	NULL
of	NULL
age	NULL
.	NULL

In	NULL
homozygous	NULL
TgB1335	NULL
mice	NULL
a	NULL
more	NULL
severe	NULL
pathology	NULL
develops	NULL
,	NULL
characterized	NULL
by	NULL
extensive	NULL
periportal	NULL
inflammation	NULL
and	NULL
tissue	NULL
necrosis	NULL
(	NULL
asterisk	NULL
)	NULL
in	NULL
the	NULL
liver	NULL
,	NULL
and	NULL
in	NULL
a	NULL
severely	NULL
hypoplas-tic	NULL
and	NULL
inflamed	NULL
pancreas	NULL
.	NULL

A	NULL
similar	NULL
histopathology	NULL
evolves	NULL
in	NULL
homozygous	NULL
TgE1335	NULL
trans	NULL
genic	NULL
mice	NULL
bred	NULL
into	NULL
a	NULL
null	NULL
TNF	NULL
background	NULL
.	NULL

Original	NULL
magnification	NULL
X108	NULL
.	NULL

Spleen	NULL
sections	NULL
from	NULL
homozygous	NULL
TgE1335	NULL
mice	NULL
are	NULL
characterized	NULL
by	NULL
markedly	NULL
reduced	NULL
numbers	NULL
of	NULL
IgM*	NULL
B	NULL
cells	NULL
(	NULL
brown	NULL
)	NULL
whereas	NULL
CD3*	NULL
T	NULL
cell	NULL
localization	NULL
-	NULL
(	NULL
blue	NULL
)	NULL
seems	NULL
unaf-fected	NULL
.	NULL

A	NULL
similar	NULL
phenotype	NULL
occurs	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
endogenous	NULL
-	NULL
TNF	NULL
.	NULL

-	NULL
Original	NULL
magnification	NULL
X114	NULL
.	NULL

Multi-Organ	NULL
Inflammation	NULL
by	NULL
Increased	NULL
Expression	NULL
of	NULL
the	NULL
D75TNF-R	NULL
100	NULL
aso	NULL
a	NULL
»	NULL
[	NULL
a	NULL
40	NULL
7	NULL
£	NULL
-	NULL
``	NULL
Tghom/p55-/-20	NULL
o	NULL
s	NULL
10	NULL
20	NULL
30	NULL
40	NULL
Days	NULL
Figure	NULL
5	NULL
.	NULL

-	NULL
Survival	NULL
of	NULL
hup75TNF-R	NULL
transgenic	NULL
mice	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TNF	NULL
or	NULL
the	NULL
p55TNF-R	NULL
.	NULL

All	NULL
TgE1335	NULL
heterozygous	NULL
mice	NULL
(	NULL
T	NULL
ghet	NULL
,	NULL
n	NULL
=	NULL
10	NULL
,	NULL
O	NULL
)	NULL
survive	NULL
usually	NULL
past	NULL
10	NULL
mo	NULL
of	NULL
age	NULL
whereas	NULL
TgE1335	NULL
homozygous	NULL
mice	NULL
(	NULL
T	NULL
ghom	NULL
,	NULL
n	NULL
=	NULL
10	NULL
,	NULL
@	NULL
)	NULL
succumb	NULL
to	NULL
the	NULL
disease	NULL
during	NULL
their	NULL
first	NULL
month	NULL
of	NULL
age	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
pSSTNF-R	NULL
(	NULL
Tghom/p55~	NULL
,	NULL
n	NULL
=	NULL
6	NULL
,	NULL
A	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
TNF	NULL
contributes	NULL
positively	NULL
but	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
the	NULL
development	NULL
of	NULL
the	NULL
lethal	NULL
pathology	NULL
(	NULL
Tghom/	NULL
TNF-	NULL
,	NULL
n	NULL
=	NULL
10	NULL
,	NULL
EW	NULL
)	NULL
.	NULL

Survival	NULL
is	NULL
measured	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
initial	NULL
number	NULL
of	NULL
animals	NULL
in	NULL
each	NULL
geno-	NULL
type	NULL
group	NULL
.	NULL

shown	NULL
that	NULL
in	NULL
vivo	NULL
NF-kB	NULL
activation	NULL
in	NULL
PBMC	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
lethality	NULL
accompanying	NULL
LPS-induced	NULL
endotoxemia	NULL
in	NULL
mice	NULL
(	NULL
32	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
signaling	NULL
through	NULL
the	NULL
p75TNF-R	NULL
is	NULL
known	NULL
to	NULL
involve	NULL
NF-KB	NULL
activating	NULL
pathways	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
was	NULL
important	NULL
to	NULL
assess	NULL
the	NULL
activation	NULL
status	NULL
of	NULL
the	NULL
NF-kB	NULL
system	NULL
in	NULL
the	NULL
p75TNF-R	NULL
transgenic	NULL
mice	NULL
.	NULL

binding	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
EMSA	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
PBMC	NULL
from	NULL
heterozygous	NULL
TgE1335	NULL
mice	NULL
at	NULL
different	NULL
developmental	NULL
points	NULL
NF-kB	NULL
binding	NULL
activity	NULL
was	NULL
found	NULL
consistently	NULL
elevated	NULL
in	NULL
PBMC	NULL
from	NULL
transgenic	NULL
versus	NULL
control	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
,	NULL
either	NULL
before	NULL
(	NULL
1	NULL
mo	NULL
of	NULL
age	NULL
)	NULL
,	NULL
during	NULL
(	NULL
2	NULL
mo	NULL
)	NULL
,	NULL
or	NULL
after	NULL
(	NULL
6	NULL
mo	NULL
)	NULL
development	NULL
of	NULL
pathology	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
simultaneous	NULL
histopathological	NULL
analysis	NULL
of	NULL
all	NULL
experimental	NULL
mice	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
a	NULL
possible	NULL
target	NULL
pathway	NULL
of	NULL
sustained	NULL
p75TNF-R	NULL
activation	NULL
in	NULL
PBMC	NULL
is	NULL
the	NULL
NF-kB	NULL
pathway	NULL
and	NULL
offer	NULL
a	NULL
mechanistic	NULL
link	NULL
to	NULL
explain	NULL
the	NULL
observed	NULL
in	NULL
vivo	NULL
inflanma-tory	NULL
activities	NULL
of	NULL
this	NULL
receptor	NULL
.	NULL

Discussion	NULL
Circulating	NULL
levels	NULL
of	NULL
soluble	NULL
TNF-Rs	NULL
are	NULL
constantly	NULL
elevated	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
clinical	NULL
conditions	NULL
including	NULL
malignant	NULL
(	NULL
46	NULL
)	NULL
,	NULL
infectious	NULL
,	NULL
and	NULL
sub-acute	NULL
or	NULL
chronic	NULL
inflammatory	NULL
or	NULL
autoimmune	NULL
diseases	NULL
(	NULL
33	NULL
,	NULL
47	NULL
)	NULL
.	NULL

In	NULL
several	NULL
of	NULL
these	NULL
conditions	NULL
,	NULL
measurement	NULL
of	NULL
sTNF-Rs	NULL
,	NULL
especially	NULL
of	NULL
the	NULL
sp75TNF-R	NULL
,	NULL
correlates	NULL
even	NULL
better	NULL
than	NULL
classical	NULL
disease-specific	NULL
markers	NULL
to	NULL
the	NULL
prognosis	NULL
,	NULL
symptoms	NULL
,	NULL
and	NULL
clinical	NULL
outcome	NULL
of	NULL
the	NULL
disease	NULL
(	NULL
33	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
sTNF-R	NULL
levels	NULL
have	NULL
a	NULL
strong	NULL
and	NULL
early	NULL
prognostic	NULL
value	NULL
for	NULL
disease	NULL
progression	NULL
in	NULL
HIV-infected	NULL
patients	NULL
(	NULL
30	NULL
)	NULL
and	NULL
in	NULL
several	NULL
inflammatory	NULL
diseases	NULL
such	NULL
as	NULL
chronic	NULL
hepatitis	NULL
virus	NULL
infections	NULL
(	NULL
25	NULL
)	NULL
,	NULL
acute	NULL
pancreatitis	NULL
(	NULL
27	NULL
)	NULL
,	NULL
acute	NULL
respiratory	NULL
distress	NULL
syndrome	NULL
(	NULL
26	NULL
)	NULL
,	NULL
SLE	NULL
(	NULL
28	NULL
)	NULL
,	NULL
and	NULL
rheumatoid	NULL
arthritis	NULL
(	NULL
29	NULL
)	NULL
.	NULL

1349	NULL
Douni	NULL
and	NULL
Kollias	NULL
Figure	NULL
6	NULL
.	NULL

Enhanced	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
PBMC	NULL
from	NULL
hup75	NULL
transgenic	NULL
mice	NULL
.	NULL

EMSA	NULL
.	NULL

of	NULL
nuclear	NULL
extracts	NULL
from	NULL
PBMC	NULL
NORMAL	NULL
-	NULL
Tg	NULL
E1335	NULL
wid	NULL
probe	NULL
Im	NULL
2m	NULL
Gm	NULL
lm	NULL
2m	NULL
6m	NULL
NEB	NULL
7	NULL
isolated	NULL
_	NULL
from	NULL
_	NULL
heterozygous	NULL
*	NULL
te	NULL
%	NULL
TgE1335	NULL
mice	NULL
or	NULL
normal	NULL
con-OCTA	NULL
-+	NULL
trol	NULL
littermates	NULL
(	NULL
=	NULL
5	NULL
per	NULL
group	NULL
)	NULL
at	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
6	NULL
mo	NULL
of	NULL
age	NULL
.	NULL

Specific	NULL
NF-kB	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
,	NULL
whereas	NULL
OCT-1	NULL
probe	NULL
acts	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
sample	NULL
loading	NULL
.	NULL

Cold	NULL
NF-kB	NULL
or	NULL
OCT-1	NULL
probe	NULL
was	NULL
used	NULL
to	NULL
indicate	NULL
specific	NULL
NF-kB	NULL
or	NULL
OCT-1	NULL
binding	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
actual	NULL
involvement	NULL
of	NULL
soluble	NULL
TNF	NULL
receptors	NULL
in	NULL
disease	NULL
pathogenesis	NULL
remains	NULL
controversial	NULL
and	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
they	NULL
may	NULL
act	NULL
both	NULL
as	NULL
antagonists	NULL
of	NULL
TNF	NULL
action	NULL
by	NULL
competing	NULL
with	NULL
its	NULL
cell	NULL
surface	NULL
receptors	NULL
,	NULL
but	NULL
also	NULL
as	NULL
ag-onists	NULL
by	NULL
protecting	NULL
TNF	NULL
from	NULL
degradation	NULL
and	NULL
therefore	NULL
stabilizing	NULL
and	NULL
enhancing	NULL
its	NULL
activity	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Shedding	NULL
of	NULL
both	NULL
TNF	NULL
receptors	NULL
occurs	NULL
in	NULL
both	NULL
a	NULL
constitutive	NULL
and	NULL
inducible	NULL
manner	NULL
,	NULL
after	NULL
appropriate	NULL
stimulation	NULL
by	NULL
a	NULL
plethora	NULL
of	NULL
immune	NULL
activating	NULL
signals	NULL
,	NULL
and	NULL
in	NULL
addition	NULL
to	NULL
providing	NULL
the	NULL
soluble	NULL
receptors	NULL
it	NULL
is	NULL
thought	NULL
to	NULL
serve	NULL
in	NULL
rendering	NULL
cells	NULL
temporarily	NULL
unresponsive	NULL
to	NULL
TNF	NULL
(	NULL
47	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
correlation	NULL
of	NULL
induced	NULL
sTNF-R	NULL
levels	NULL
with	NULL
enhanced	NULL
expression	NULL
of	NULL
their	NULL
cell	NULL
surface	NULL
precursors	NULL
in	NULL
specific	NULL
cell	NULL
types	NULL
remains	NULL
possible	NULL
,	NULL
especially	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
p75TNF-R	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
which	NULL
is	NULL
known	NULL
to	NULL
be	NULL
highly	NULL
inducible	NULL
by	NULL
the	NULL
same	NULL
signals	NULL
that	NULL
mediate	NULL
its	NULL
induced	NULL
shedding	NULL
(	NULL
38	NULL
,	NULL
47	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
as	NULL
shown	NULL
clearly	NULL
in	NULL
this	NULL
study	NULL
,	NULL
sustained	NULL
upregulation	NULL
of	NULL
human	NULL
p75TNF-R	NULL
production	NULL
in	NULL
transgenic	NULL
mice	NULL
,	NULL
leads	NULL
to	NULL
both	NULL
an	NULL
upregulated	NULL
level	NULL
of	NULL
shed	NULL
soluble	NULL
receptors	NULL
but	NULL
also	NULL
to	NULL
a	NULL
chronic	NULL
accumulation	NULL
of	NULL
the	NULL
receptor	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
increased	NULL
levels	NULL
of	NULL
shed	NULL
p75TNF-Rs	NULL
,	NULL
as	NULL
seen	NULL
in	NULL
human	NULL
diseases	NULL
,	NULL
reflect	NULL
a	NULL
similar	NULL
upregulation	NULL
of	NULL
the	NULL
cell	NULL
surface	NULL
form	NULL
of	NULL
the	NULL
receptor	NULL
,	NULL
which	NULL
may	NULL
interfere	NULL
with	NULL
immune	NULL
homeostasis	NULL
and/	NULL
or	NULL
pathogenesis	NULL
.	NULL

Notably	NULL
,	NULL
the	NULL
severity	NULL
of	NULL
the	NULL
inflammatory	NULL
phenotypes	NULL
developing	NULL
in	NULL
transgenic	NULL
lines	NULL
expressing	NULL
hup75TNF-R	NULL
transgenes	NULL
correlates	NULL
positively	NULL
with	NULL
the	NULL
levels	NULL
of	NULL
soluble	NULL
human	NULL
p75TNF-R	NULL
measured	NULL
in	NULL
diseased	NULL
sera	NULL
.	NULL

For	NULL
example	NULL
,	NULL
heterozygous	NULL
TgE1334	NULL
mice	NULL
constitutively	NULL
expressing	NULL
only	NULL
double	NULL
the	NULL
physiological	NULL
levels	NULL
of	NULL
p75TNF-R	NULL
s	NULL
do	NULL
not	NULL
show	NULL
any	NULL
signs	NULL
of	NULL
pathology	NULL
,	NULL
whereas	NULL
heterozygous	NULL
TgE1335	NULL
mice	NULL
producing	NULL
four-	NULL
to	NULL
fivefold	NULL
higher	NULL
levels	NULL
develop	NULL
a	NULL
chronic	NULL
inflammatory	NULL
disease	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
homozygous	NULL
TgE1335	NULL
mice	NULL
developing	NULL
a	NULL
most	NULL
severe	NULL
multi-organ	NULL
inflammatory	NULL
phenotype	NULL
are	NULL
found	NULL
to	NULL
constitutively	NULL
produce	NULL
twofold	NULL
increased	NULL
levels	NULL
of	NULL
total	NULL
sp75TNF-R	NULL
s	NULL
in	NULL
comparison	NULL
to	NULL
the	NULL
levels	NULL
measured	NULL
for	NULL
endogenous	NULL
p75TNF-R	NULL
s	NULL
in	NULL
sera	NULL
from	NULL
endotoxemic	NULL
(	NULL
LPS-treated	NULL
)	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
serum	NULL
sp75TNF-R	NULL
levels	NULL
measured	NULL
in	NULL
several	NULL
human	NULL
inflammatory	NULL
diseases	NULL
,	NULL
including	NULL
AIDS	NULL
,	NULL
are	NULL
usually	NULL
two-	NULL
to	NULL
fourfold	NULL
increased	NULL
over	NULL
normal	NULL
individuals	NULL
(	NULL
25-30	NULL
)	NULL
,	NULL
whereas	NULL
even	NULL
higher	NULL
levels	NULL
have	NULL
been	NULL
recorded	NULL
in	NULL
septic	NULL
shock	NULL
patients	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Taken	NULL
to-gether	NULL
,	NULL
our	NULL
results	NULL
show	NULL
that	NULL
at	NULL
levels	NULL
similar	NULL
to	NULL
those	NULL
seen	NULL
in	NULL
human	NULL
disease	NULL
,	NULL
chronic	NULL
induced	NULL
production	NULL
of	NULL
the	NULL
p75TNF	NULL
receptor	NULL
in	NULL
vivo	NULL
,	NULL
has	NULL
detrimental	NULL
effects	NULL
to	NULL
physi-	NULL
ological	NULL
homeostasis	NULL
and	NULL
leads	NULL
to	NULL
a	NULL
multi-organ	NULL
inflammatory	NULL
syndrome	NULL
in	NULL
mice	NULL
.	NULL

Furthermore	NULL
,	NULL
they	NULL
demonstrate	NULL
that	NULL
the	NULL
severity	NULL
of	NULL
the	NULL
in	NULL
vivo	NULL
proinflammatory	NULL
activities	NULL
of	NULL
the	NULL
p75TNF-R	NULL
correlate	NULL
positively	NULL
with	NULL
its	NULL
chronic	NULL
level	NULL
of	NULL
production	NULL
.	NULL

Although	NULL
our	NULL
current	NULL
knowledge	NULL
of	NULL
the	NULL
involvement	NULL
of	NULL
the	NULL
TNF/p55TNF-R	NULL
pair	NULL
in	NULL
disease	NULL
pathogenesis	NULL
is	NULL
quite	NULL
advanced	NULL
,	NULL
understanding	NULL
of	NULL
the	NULL
in	NULL
vivo	NULL
function	NULL
of	NULL
the	NULL
p75TNF-R	NULL
remains	NULL
vague	NULL
.	NULL

Recent	NULL
studies	NULL
in	NULL
p75TNF-R	NULL
knockout	NULL
mice	NULL
have	NULL
failed	NULL
to	NULL
show	NULL
a	NULL
specific	NULL
function	NULL
for	NULL
this	NULL
receptor	NULL
in	NULL
physiology	NULL
or	NULL
in	NULL
experimental	NULL
models	NULL
of	NULL
TNF-mediated	NULL
disease	NULL
(	NULL
18	NULL
,	NULL
48	NULL
)	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
its	NULL
profound	NULL
involvement	NULL
in	NULL
the	NULL
cerebral	NULL
complications	NULL
of	NULL
experimental	NULL
malaria	NULL
(	NULL
49	NULL
)	NULL
or	NULL
in	NULL
the	NULL
allergen-induced	NULL
migration	NULL
of	NULL
Langerhans	NULL
cells	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
view	NULL
of	NULL
the	NULL
almost	NULL
uniquely	NULL
known	NULL
in	NULL
vitro	NULL
activities	NULL
of	NULL
this	NULL
receptor	NULL
on	NULL
thymocyte/	NULL
T	NULL
lymphocyte	NULL
proliferation	NULL
(	NULL
42	NULL
)	NULL
,	NULL
or	NULL
in	NULL
the	NULL
activation	NULL
induced	NULL
apoptosis	NULL
of	NULL
CD8*	NULL
T	NULL
cells	NULL
(	NULL
51	NULL
)	NULL
,	NULL
it	NULL
was	NULL
quite	NULL
surprising	NULL
that	NULL
thymocytes	NULL
and	NULL
lymphocytes	NULL
in	NULL
p75TNF-R	NULL
knockout	NULL
mice	NULL
were	NULL
normal	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
failure	NULL
to	NULL
demonstrate	NULL
an	NULL
in	NULL
vivo	NULL
independent	NULL
activity	NULL
of	NULL
the	NULL
p75TNF-R	NULL
in	NULL
the	NULL
knockout	NULL
system	NULL
,	NULL
together	NULL
with	NULL
ample	NULL
evidence	NULL
for	NULL
a	NULL
partial	NULL
agonistic	NULL
role	NULL
of	NULL
this	NULL
receptor	NULL
in	NULL
TNF/pS5TNF-R	NULL
-mediated	NULL
responses	NULL
(	NULL
14	NULL
,	NULL
52	NULL
,	NULL
53	NULL
)	NULL
has	NULL
led	NULL
to	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
p75TNF-R	NULL
serves	NULL
an	NULL
accessory	NULL
role	NULL
in	NULL
enhancing	NULL
-mediated	NULL
signaling	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
all	NULL
cases	NULL
where	NULL
p75TNF-R-specific	NULL
signaling	NULL
has	NULL
been	NULL
observed	NULL
,	NULL
a	NULL
high	NULL
density	NULL
of	NULL
this	NULL
receptor	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
was	NULL
re-quired	NULL
,	NULL
suggesting	NULL
that	NULL
inducibility	NULL
of	NULL
this	NULL
receptor	NULL
is	NULL
a	NULL
prerequisite	NULL
for	NULL
function	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
receptors	NULL
through	NULL
induced	NULL
aggregation	NULL
is	NULL
a	NULL
widespread	NULL
phenomenon	NULL
in	NULL
cytokine	NULL
and	NULL
growth	NULL
factor	NULL
signaling	NULL
(	NULL
54	NULL
,	NULL
55	NULL
)	NULL
.	NULL

Ligand-induced	NULL
clustering	NULL
of	NULL
receptors	NULL
seems	NULL
to	NULL
be	NULL
a	NULL
primary	NULL
control	NULL
mechanism	NULL
,	NULL
in	NULL
particular	NULL
for	NULL
constitutively	NULL
produced	NULL
receptors	NULL
,	NULL
such	NULL
as	NULL
the	NULL
pSSTNF-R.	NULL
On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
there	NULL
is	NULL
substantial	NULL
evidence	NULL
in	NULL
vitro	NULL
,	NULL
that	NULL
induced	NULL
production	NULL
of	NULL
such	NULL
members	NULL
of	NULL
the	NULL
TNF-R	NULL
family	NULL
as	NULL
the	NULL
p75	NULL
(	NULL
45	NULL
,	NULL
56	NULL
)	NULL
or	NULL
the	NULL
pS55TNF-R	NULL
(	NULL
57	NULL
)	NULL
,	NULL
Fas	NULL
(	NULL
57	NULL
)	NULL
,	NULL
CD40	NULL
(	NULL
45	NULL
,	NULL
58	NULL
)	NULL
,	NULL
or	NULL
p75NGF-R	NULL
(	NULL
59	NULL
)	NULL
and	NULL
the	NULL
tyrosine	NULL
kinase	NULL
receptors	NULL
for	NULL
growth	NULL
factors	NULL
(	NULL
60	NULL
)	NULL
may	NULL
lead	NULL
to	NULL
spontaneous	NULL
signaling	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
ligand	NULL
.	NULL

O	NULL
ur	NULL
present	NULL
data	NULL
are	NULL
in	NULL
support	NULL
of	NULL
a	NULL
physiologically	NULL
significant	NULL
role	NULL
for	NULL
ligand-independent	NULL
signaling	NULL
in	NULL
vivo	NULL
,	NULL
especially	NULL
for	NULL
the	NULL
p75TNF-R	NULL
which	NULL
is	NULL
known	NULL
to	NULL
be	NULL
highly	NULL
induced	NULL
in	NULL
pathological	NULL
conditions	NULL
.	NULL

However	NULL
,	NULL
it	NULL
remains	NULL
possible	NULL
that	NULL
yet	NULL
unidentified	NULL
ligands	NULL
may	NULL
contribute	NULL
to	NULL
its	NULL
observed	NULL
activation	NULL
.	NULL

Our	NULL
evidence	NULL
that	NULL
sustained	NULL
p75TNF-R	NULL
overproduction	NULL
in	NULL
mice	NULL
may	NULL
lead	NULL
to	NULL
inflammatory	NULL
complications	NULL
involving	NULL
several	NULL
vital	NULL
tissues	NULL
and	NULL
organs	NULL
,	NULL
has	NULL
important	NULL
implications	NULL
for	NULL
inflammatory	NULL
disease	NULL
pathogenesis	NULL
in	NULL
humans	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
a	NULL
recent	NULL
study	NULL
addressing	NULL
kinetics	NULL
of	NULL
production	NULL
of	NULL
soluble	NULL
TNF-R	NULL
after	NULL
leakage	NULL
of	NULL
high	NULL
doses	NULL
of	NULL
TNF	NULL
in	NULL
the	NULL
circulation	NULL
of	NULL
patients	NULL
undergoing	NULL
isolated	NULL
limb	NULL
perfusion	NULL
therapy	NULL
(	NULL
31	NULL
)	NULL
,	NULL
it	NULL
has	NULL
been	NULL
observed	NULL
that	NULL
levels	NULL
of	NULL
soluble	NULL
p75TNF-R	NULL
remain	NULL
high	NULL
,	NULL
long	NULL
after	NULL
TNF	NULL
disappears	NULL
from	NULL
the	NULL
circulation	NULL
,	NULL
suggesting	NULL
a	NULL
TNF-independent	NULL
regulation	NULL
of	NULL
the	NULL
production	NULL
and	NULL
perhaps	NULL
function	NULL
of	NULL
this	NULL
receptor	NULL
.	NULL

The	NULL
surprising	NULL
finding	NULL
in	NULL
this	NULL
study	NULL
,	NULL
that	NULL
the	NULL
inflammatory	NULL
activities	NULL
of	NULL
the	NULL
p75TNF-R	NULL
occur	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TNF	NULL
,	NULL
offers	NULL
a	NULL
novel	NULL
mechanism	NULL
for	NULL
p75TNF-R	NULL
functioning	NULL
which	NULL
may	NULL
be	NULL
of	NULL
pivotal	NULL
importance	NULL
in	NULL
many	NULL
clinical	NULL
conditions	NULL
including	NULL
sepsis	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
although	NULL
the	NULL
TNF/	NULL
p55TNF-R	NULL
system	NULL
seems	NULL
to	NULL
operate	NULL
only	NULL
in	NULL
an	NULL
initial	NULL
narrow	NULL
window	NULL
of	NULL
time	NULL
during	NULL
clinical	NULL
sepsis	NULL
(	NULL
61	NULL
)	NULL
,	NULL
sp75TNF-R	NULL
levels	NULL
are	NULL
found	NULL
constantly	NULL
elevated	NULL
,	NULL
correlate	NULL
positively	NULL
with	NULL
sepsis	NULL
scores	NULL
and	NULL
show	NULL
maximal	NULL
values	NULL
in	NULL
patients	NULL
that	NULL
do	NULL
not	NULL
survive	NULL
(	NULL
24	NULL
)	NULL
.	NULL

After	NULL
the	NULL
disappointing	NULL
neutral	NULL
outcome	NULL
of	NULL
anti-TNF	NULL
trials	NULL
in	NULL
sepsis	NULL
,	NULL
and	NULL
taking	NULL
into	NULL
account	NULL
the	NULL
adverse	NULL
effects	NULL
of	NULL
enhanced	NULL
p75TNF-R	NULL
production	NULL
as	NULL
presented	NULL
in	NULL
this	NULL
study	NULL
,	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
specific	NULL
antagonism	NULL
of	NULL
this	NULL
receptor	NULL
may	NULL
be	NULL
beneficial	NULL
even	NULL
at	NULL
late	NULL
phases	NULL
of	NULL
severe	NULL
sepsis	NULL
,	NULL
but	NULL
also	NULL
during	NULL
the	NULL
course	NULL
of	NULL
many	NULL
other	NULL
human	NULL
inflammatory	NULL
pathologies	NULL
where	NULL
a	NULL
positive	NULL
correlation	NULL
between	NULL
soluble	NULL
p75TNF-R	NULL
and	NULL
disease	NULL
progression	NULL
has	NULL
been	NULL
observed	NULL
.	NULL

The	NULL
human	NULL
p75TNF-R	NULL
expressing	NULL
transgenic	NULL
lines	NULL
presented	NULL
in	NULL
this	NULL
study	NULL
should	NULL
offer	NULL
a	NULL
useful	NULL
model	NULL
system	NULL
to	NULL
develop	NULL
and	NULL
test	NULL
the	NULL
in	NULL
vivo	NULL
efficacy	NULL
of	NULL
such	NULL
p75TNF-R	NULL
antagonistic	NULL
substances	NULL
.	NULL

We	NULL
wish	NULL
to	NULL
thank	NULL
Dr.	NULL
Horst	NULL
Bluethmann	NULL
for	NULL
providing	NULL
the	NULL
p55STNF-R	NULL
knockout	NULL
mice	NULL
;	NULL
Dr.	NULL
Mark	NULL
Moore	NULL
for	NULL
providing	NULL
the	NULL
p75TNF-R	NULL
knockout	NULL
mice	NULL
;	NULL
the	NULL
Genentech	NULL
manufacturing	NULL
group	NULL
for	NULL
the	NULL
recombinant	NULL
human	NULL
TNF	NULL
;	NULL
Dr.	NULL
Matthias	NULL
Grell	NULL
for	NULL
the	NULL
M80	NULL
polyclonal	NULL
anti-human	NULL
p75TNF-R	NULL
antibody	NULL
;	NULL
Dr.	NULL
Wim	NULL
Buurman	NULL
for	NULL
the	NULL
murine	NULL
and	NULL
human	NULL
p75TNF-R	NULL
-specific	NULL
ELISA	NULL
;	NULL
Dr.	NULL
Steve	NULL
Cobbold	NULL
for	NULL
the	NULL
KT	NULL
3	NULL
anti-CD3	NULL
antibody	NULL
;	NULL
Dr.	NULL
R	NULL
oly	NULL
Foulkes	NULL
for	NULL
the	NULL
€BO006	NULL
anti-human	NULL
TNF	NULL
antibody	NULL
;	NULL
Dr.	NULL
Stavroula	NULL
Kousteni	NULL
for	NULL
helpful	NULL
advice	NULL
on	NULL
EMSA	NULL
protocols	NULL
;	NULL
and	NULL
finally	NULL
Spiridoula	NULL
Papandreou	NULL
and	NULL
Spiros	NULL
Lalos	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
project	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Hellenic	NULL
Secretariat	NULL
for	NULL
Research	NULL
and	NULL
Technology	NULL
and	NULL
European	NULL
Commission	NULL
Grants	NULL
BIO4-CT96-0077	NULL
and	NULL
BIO4-CT96-0174	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
George	NULL
Kollias	NULL
,	NULL
Department	NULL
of	NULL
Molecular	NULL
Genetics	NULL
,	NULL
Hellenic	NULL
Pasteur	NULL
Institute	NULL
,	NULL
127	NULL
Vas	NULL
.	NULL

Sophias	NULL
Avenue	NULL
,	NULL
115	NULL
21	NULL
Athens	NULL
,	NULL
Hellas	NULL
Tel	NULL
.	NULL

:	NULL
30	NULL
1	NULL
6455071	NULL
.	NULL

Fax	NULL
:	NULL
30	NULL
1	NULL
6456547	NULL
.	NULL

E-mail	NULL
:	NULL
giorgos_kollias	NULL
@	NULL
hol.gr	NULL
Received	NULL
for	NULL
publication	NULL
19	NULL
June	NULL
1998	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
29	NULL
July	NULL
1998	NULL
.	NULL

1350	NULL
Multi-	NULL
Organ	NULL
Inflammation	NULL
by	NULL
Increased	NULL
Expression	NULL
of	NULL
the	NULL
D75STNF-R	NULL
References	NULL
1	NULL
.	NULL

2	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

Vassalli	NULL
,	NULL
P.	NULL
1992	NULL
.	NULL

The	NULL
pathophysiology	NULL
of	NULL
tumor	NULL
necrosis	NULL
fac-tors	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10:411-452	NULL
.	NULL

Vandenabeele	NULL
,	NULL
P.	NULL
,	NULL
W.	NULL
Declereq	NULL
,	NULL
R.	NULL
Beyaert	NULL
,	NULL
and	NULL
W.	NULL
Fiers	NULL
.	NULL

1995	NULL
.	NULL

Two	NULL
tumour	NULL
necrosis	NULL
factor	NULL
receptors	NULL
:	NULL
structure	NULL
and	NULL
function	NULL
.	NULL

Trends	NULL
Cell	NULL
.	NULL

Biol	NULL
.	NULL

5:392-399.	NULL
.	NULL

Aggarwal	NULL
,	NULL
B.B	NULL
.	NULL

,	NULL
and	NULL
K.	NULL
Natarajan	NULL
.	NULL

1996	NULL
.	NULL

Tumor	NULL
necrosis	NULL
fac-	NULL
tors	NULL
:	NULL
Developments	NULL
during	NULL
the	NULL
last	NULL
decade	NULL
.	NULL

Eur	NULL
Cytokine	NULL
Netw	NULL
.	NULL

7:93-124.	NULL
.	NULL

Seckinger	NULL
,	NULL
P.	NULL
,	NULL
S.	NULL
Isaaz	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Dayer	NULL
.	NULL

1989	NULL
.	NULL

Purification	NULL
and	NULL
biologic	NULL
characterization	NULL
of	NULL
a	NULL
specific	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
inhibitor	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264:11966-11973.	NULL
.	NULL

Engelmann	NULL
,	NULL
H.	NULL
,	NULL
D.	NULL
Novick	NULL
,	NULL
and	NULL
D.	NULL
Wallach	NULL
.	NULL

1990	NULL
.	NULL

Two	NULL
tu-	NULL
mor	NULL
necrosis	NULL
factor-binding	NULL
proteins	NULL
purified	NULL
from	NULL
human	NULL
urine	NULL
.	NULL

Evidence	NULL
for	NULL
immunological	NULL
cross-reactivity	NULL
with	NULL
cell	NULL
surface	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptors	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
:	NULL
1531-1536.	NULL
.	NULL

Pasparakis	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Alexopoulou	NULL
,	NULL
V.	NULL
Episkopou	NULL
,	NULL
and	NULL
G.	NULL
Kollias	NULL
.	NULL

1996	NULL
.	NULL

Immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
in	NULL
TNFa-defi-cient	NULL
mice	NULL
:	NULL
a	NULL
critical	NULL
requirement	NULL
for	NULL
TNFa	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
primary	NULL
B	NULL
cell	NULL
follicles	NULL
,	NULL
follicular	NULL
dendritic	NULL
cell	NULL
networks	NULL
and	NULL
germinal	NULL
centers	NULL
,	NULL
and	NULL
in	NULL
the	NULL
maturation	NULL
of	NULL
the	NULL
humoral	NULL
immune	NULL
response	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:1397-1411.	NULL
.	NULL

Le	NULL
Hir	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Bluethmann	NULL
,	NULL
MH	NULL
.	NULL

Kosco-Vilbois	NULL
,	NULL
M.	NULL
Muller	NULL
,	NULL
F.	NULL
Di	NULL
Padova	NULL
,	NULL
M.	NULL
Moore	NULL
,	NULL
B.	NULL
R	NULL
yffel	NULL
,	NULL
and	NULL
H.P	NULL
.	NULL

Eug-ster	NULL
.	NULL

1996	NULL
.	NULL

Differentiation	NULL
of	NULL
follicular	NULL
dendritic	NULL
cells	NULL
and	NULL
full	NULL
antibody	NULL
responses	NULL
require	NULL
tumour	NULL
necrosis	NULL
factor	NULL
receptor-	NULL
1	NULL
signalling	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:2367-2373.	NULL
.	NULL

Neumann	NULL
,	NULL
B.	NULL
,	NULL
T.	NULL
Machleidt	NULL
,	NULL
A.	NULL
Lifka	NULL
,	NULL
K.	NULL
Pfeffer	NULL
,	NULL
D.	NULL
Vestwe-	NULL
ber	NULL
,	NULL
TW	NULL
.	NULL

Mak	NULL
,	NULL
B.	NULL
Holzmann	NULL
,	NULL
and	NULL
M.	NULL
Kronke	NULL
.	NULL

1996	NULL
.	NULL

Crucial	NULL
role	NULL
of	NULL
55-kilodalton	NULL
TNF	NULL
receptor	NULL
in	NULL
TNF-induced	NULL
adhesion	NULL
molecule	NULL
expression	NULL
and	NULL
leukocyte	NULL
organ	NULL
infiltration	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:1587-1593.	NULL
.	NULL

Rothe	NULL
,	NULL
J.	NULL
,	NULL
W.	NULL
Lesslauer	NULL
,	NULL
H.	NULL
Lotscher	NULL
,	NULL
Y.	NULL
Lang	NULL
,	NULL
P.	NULL
Koebel	NULL
,	NULL
F.	NULL
Kontgen	NULL
,	NULL
A.	NULL
Althage	NULL
,	NULL
R.	NULL
Zinkernagel	NULL
,	NULL
M.	NULL
Steinmetz	NULL
,	NULL
and	NULL
H.	NULL
Bluethmann	NULL
.	NULL

1993	NULL
.	NULL

Mice	NULL
lacking	NULL
the	NULL
tumour	NULL
necrosis	NULL
factor	NULL
receptor	NULL
1	NULL
are	NULL
resistant	NULL
to	NULL
TNF-mediated	NULL
toxicity	NULL
but	NULL
highly	NULL
susceptible	NULL
to	NULL
infection	NULL
by	NULL
Listeria	NULL
monocytogenes	NULL
.	NULL

Nature	NULL
.	NULL

364:798-802	NULL
.	NULL

Pfeffer	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Matsuyama	NULL
,	NULL
TM	NULL
.	NULL

Kundig	NULL
,	NULL
A.	NULL
Wakeham	NULL
,	NULL
K.	NULL
Kishihara	NULL
,	NULL
A.	NULL
Shahinian	NULL
,	NULL
K.	NULL
Wiegmann	NULL
,	NULL
P.S	NULL
.	NULL

Ohashi	NULL
,	NULL
M.	NULL
Kronke	NULL
,	NULL
and	NULL
T.W	NULL
.	NULL

Mak	NULL
.	NULL

1993	NULL
.	NULL

Mice	NULL
deficient	NULL
for	NULL
the	NULL
55kd	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
are	NULL
resistant	NULL
to	NULL
endotoxic	NULL
shock	NULL
,	NULL
yet	NULL
succumb	NULL
to	NULL
L.	NULL
monocytogenes	NULL
infection	NULL
.	NULL

Cell	NULL
.	NULL

73	NULL
:	NULL
457-467	NULL
.	NULL

Ruby	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Bluethmann	NULL
,	NULL
and	NULL
J.J.	NULL
Peschon	NULL
.	NULL

1997	NULL
.	NULL

Antiviral	NULL
activity	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
is	NULL
mediated	NULL
via	NULL
p55	NULL
and	NULL
p75	NULL
TNF	NULL
receptors	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1591-1596	NULL
.	NULL

Douni	NULL
,	NULL
E.	NULL
,	NULL
K.	NULL
Akassoglou	NULL
,	NULL
L.	NULL
Alexopoulou	NULL
,	NULL
S.	NULL
Georgopoulos	NULL
,	NULL
S.	NULL
Haralambous	NULL
,	NULL
S.	NULL
Hill	NULL
,	NULL
G.	NULL
Kassiotis	NULL
,	NULL
D.	NULL
Kontoyiannis	NULL
,	NULL
M.	NULL
Pasparakis	NULL
,	NULL
D.	NULL
Plows	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

Transgenic	NULL
and	NULL
knockout	NULL
analyses	NULL
of	NULL
the	NULL
role	NULL
of	NULL
TNF	NULL
in	NULL
immune	NULL
regulation	NULL
and	NULL
disease	NULL
pathogenesis	NULL
.	NULL

J	NULL
Inflamm	NULL
.	NULL

47:27-38	NULL
.	NULL

Akassoglou	NULL
,	NULL
K.	NULL
,	NULL
L.	NULL
Probert	NULL
,	NULL
G.	NULL
Kontogeorgos	NULL
,	NULL
and	NULL
G.	NULL
Kollias	NULL
.	NULL

1997	NULL
.	NULL

Astrocyte-specific	NULL
but	NULL
not	NULL
neuron-specific	NULL
transmembrane	NULL
TNF	NULL
triggers	NULL
inflammation	NULL
and	NULL
degeneration	NULL
in	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
of	NULL
transgenic	NULL
mice	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

158	NULL
:	NULL
438-445	NULL
.	NULL

Alexopoulou	NULL
,	NULL
L.	NULL
,	NULL
M.	NULL
Pasparakis	NULL
,	NULL
and	NULL
G.	NULL
Kollias	NULL
.	NULL

1997	NULL
.	NULL

A	NULL
murine	NULL
transmembrane	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
transgene	NULL
induces	NULL
arthritis	NULL
by	NULL
cooperative	NULL
p55/p75	NULL
TNF	NULL
receptor	NULL
signalling	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

27:2588-2592	NULL
.	NULL

Probert	NULL
,	NULL
L.	NULL
,	NULL
J.	NULL
Keffer	NULL
,	NULL
P.	NULL
Corbella	NULL
,	NULL
H.	NULL
Cazlaris	NULL
,	NULL
E.	NULL
Patsavoudi	NULL
,	NULL
1351	NULL
Douni	NULL
and	NULL
Kollias	NULL
16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

S.	NULL
Stephens	NULL
,	NULL
E.	NULL
Kaslaris	NULL
,	NULL
D.	NULL
Kioussis	NULL
,	NULL
and	NULL
G.	NULL
Kollias	NULL
1993	NULL
.	NULL

Wasting	NULL
,	NULL
ischemia	NULL
and	NULL
lymphoid	NULL
abnormalities	NULL
in	NULL
mice	NULL
expressing	NULL
T-cell	NULL
targeted	NULL
human	NULL
tumor	NULL
necrosis	NULL
factor	NULL
trans	NULL
genes	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

151:1894-1906	NULL
.	NULL

Georgopoulos	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
Plows	NULL
,	NULL
and	NULL
G.	NULL
Kollias	NULL
1996	NULL
.	NULL

Transmembrane	NULL
TNF	NULL
is	NULL
sufficient	NULL
to	NULL
induce	NULL
localized	NULL
tissue	NULL
toxicity	NULL
and	NULL
chronic	NULL
inflammatory	NULL
arthritis	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

J.	NULL
Inflamm	NULL
.	NULL

46:86-97	NULL
.	NULL

Kondo	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
D.N	NULL
.	NULL

Sauder	NULL
.	NULL

1997	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
receptor	NULL
type	NULL
1	NULL
(	NULL
p55	NULL
)	NULL
is	NULL
a	NULL
main	NULL
mediator	NULL
for	NULL
TNF-	NULL
«	NULL
-induced	NULL
skin	NULL
inflammation	NULL
.	NULL

Eur	NULL
:	NULL
J	NULL
Immunol	NULL
.	NULL

27:1713-1718	NULL
.	NULL

Erickson	NULL
,	NULL
SL	NULL
.	NULL

,	NULL
F.J.	NULL
De	NULL
Sauvage	NULL
,	NULL
K.	NULL
Kikly	NULL
,	NULL
K.	NULL
Carver-Moore	NULL
,	NULL
S.	NULL
Pitts	NULL
Meek	NULL
,	NULL
N.	NULL
Gillett	NULL
,	NULL
K.C	NULL
.	NULL

Sheehan	NULL
,	NULL
R.D	NULL
.	NULL

Schreiber	NULL
,	NULL
D.V	NULL
.	NULL

Goeddel	NULL
,	NULL
and	NULL
M.W	NULL
.	NULL

Moore	NULL
.	NULL

1994	NULL
.	NULL

Decreased	NULL
sensitivity	NULL
to	NULL
tumour-necrosis	NULL
factor	NULL
but	NULL
normal	NULL
T-cell	NULL
development	NULL
in	NULL
TNF	NULL
receptor-2-deficient	NULL
mice	NULL
.	NULL

Nature	NULL
.	NULL

372:560-563	NULL
.	NULL

Grell	NULL
,	NULL
M.	NULL
,	NULL
E.	NULL
Douni	NULL
,	NULL
H.	NULL
Wajant	NULL
,	NULL
M.	NULL
Lohden	NULL
,	NULL
M.	NULL
Clauss	NULL
,	NULL
B.	NULL
Maxeiner	NULL
,	NULL
S.	NULL
Georgopoulos	NULL
,	NULL
W.	NULL
Lesslauer	NULL
,	NULL
G.	NULL
Kollias	NULL
,	NULL
K.	NULL
Pfi-zenmaier	NULL
,	NULL
and	NULL
P.	NULL
Scheurich	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
transmembrane	NULL
form	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
is	NULL
the	NULL
prime	NULL
activating	NULL
ligand	NULL
of	NULL
the	NULL
80	NULL
kDa	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
.	NULL

Céll	NULL
.	NULL

83:793-802	NULL
.	NULL

Grell	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Wajant	NULL
,	NULL
G.	NULL
Zimmermann	NULL
,	NULL
and	NULL
P.	NULL
Scheurich	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
type	NULL
1	NULL
receptor	NULL
(	NULL
CD120a	NULL
)	NULL
is	NULL
the	NULL
high-affinity	NULL
receptor	NULL
for	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Aad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

95:570-575	NULL
.	NULL

Vandenabeele	NULL
,	NULL
P.	NULL
,	NULL
W.	NULL
Declereq	NULL
,	NULL
B.	NULL
Vanhaesebroeck	NULL
,	NULL
J.	NULL
Grooten	NULL
,	NULL
and	NULL
W.	NULL
Fiers	NULL
1995	NULL
.	NULL

Both	NULL
TNF	NULL
receptors	NULL
are	NULL
required	NULL
for	NULL
TNF-mediated	NULL
induction	NULL
of	NULL
apoptosis	NULL
in	NULL
PC6O	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

154:2904-2913	NULL
.	NULL

Haridas	NULL
,	NULL
V.	NULL
,	NULL
B.G	NULL
.	NULL

Darnay	NULL
,	NULL
K.	NULL
Natarajan	NULL
,	NULL
R.	NULL
Heller	NULL
,	NULL
and	NULL
B.B	NULL
.	NULL

Aggarwal	NULL
.	NULL

1998	NULL
.	NULL

Overexpression	NULL
of	NULL
the	NULL
p80	NULL
TNF	NULL
receptor	NULL
leads	NULL
to	NULL
TNF-dependent	NULL
apoptosis	NULL
,	NULL
nuclear	NULL
factor-KB	NULL
activa-tion	NULL
,	NULL
and	NULL
c-Jun	NULL
kinase	NULL
activation	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

160:3152-3162	NULL
.	NULL

Santee	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
and	NULL
LB	NULL
.	NULL

Owen-Schaub	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
p75/	NULL
80	NULL
(	NULL
CD120b	NULL
)	NULL
gene	NULL
structure	NULL
and	NULL
promoter	NULL
characterization	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:21151-21159	NULL
.	NULL

Schroder	NULL
,	NULL
J.	NULL
,	NULL
F.	NULL
Stuber	NULL
,	NULL
H.	NULL
Gallati	NULL
,	NULL
F.U	NULL
.	NULL

Schade	NULL
,	NULL
and	NULL
B.	NULL
Kre-mer	NULL
.	NULL

1995	NULL
.	NULL

Pattern	NULL
of	NULL
soluble	NULL
TNF	NULL
receptors	NULL
I	NULL
and	NULL
II	NULL
in	NULL
sepsis	NULL
.	NULL

Infection	NULL
.	NULL

23:143-148	NULL
.	NULL

Marinos	NULL
,	NULL
G.	NULL
,	NULL
N.V.	NULL
Naoumov	NULL
,	NULL
S.	NULL
Rossol	NULL
,	NULL
F.	NULL
Torre	NULL
,	NULL
P.Y	NULL
.	NULL

Wong	NULL
,	NULL
H.	NULL
Gallati	NULL
,	NULL
B.	NULL
Portmann	NULL
,	NULL
and	NULL
R.	NULL
Williams	NULL
.	NULL

1995	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
receptors	NULL
in	NULL
patients	NULL
with	NULL
chronic	NULL
hepatitis	NULL
B	NULL
virus	NULL
infection	NULL
.	NULL

Gastmentervlogy	NULL
.	NULL

108:1453-1463	NULL
.	NULL

Lucas	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
Lou	NULL
,	NULL
D.R	NULL
.	NULL

Morel	NULL
,	NULL
B.	NULL
Ricou	NULL
,	NULL
P.M.	NULL
Suter	NULL
,	NULL
and	NULL
G.E	NULL
.	NULL

Grau	NULL
.	NULL

1997	NULL
.	NULL

TNF	NULL
receptors	NULL
in	NULL
the	NULL
microvascular	NULL
pathology	NULL
of	NULL
acute	NULL
respiratory	NULL
distress	NULL
syndrome	NULL
and	NULL
cerebral	NULL
malaria	NULL
.	NULL

J	NULL
Leukoc	NULL
Biol	NULL
.	NULL

61:551-558	NULL
.	NULL

De	NULL
Beaux	NULL
,	NULL
A.C.	NULL
,	NULL
J.A	NULL
.	NULL

Goldie	NULL
,	NULL
D.C.	NULL
Ross	NULL
,	NULL
D.C.	NULL
Carter	NULL
,	NULL
and	NULL
K.C.H	NULL
.	NULL

Fearon	NULL
.	NULL

1996	NULL
.	NULL

Serum	NULL
concentrations	NULL
of	NULL
inflammatory	NULL
mediators	NULL
related	NULL
to	NULL
organ	NULL
failure	NULL
in	NULL
patients	NULL
with	NULL
acute	NULL
pan-creatitis	NULL
.	NULL

British	NULL
J	NULL
.	NULL

Surgery	NULL
.	NULL

$	NULL
3:349-353	NULL
.	NULL

Gabay	NULL
,	NULL
C.	NULL
,	NULL
N.	NULL
Cakir	NULL
,	NULL
F.	NULL
Moral	NULL
,	NULL
P.	NULL
Roux-Lombard	NULL
,	NULL
O.	NULL
Meyer	NULL
,	NULL
J.M	NULL
.	NULL

Dayer	NULL
,	NULL
T.	NULL
Vischer	NULL
,	NULL
H.	NULL
Yazici	NULL
,	NULL
and	NULL
P.A	NULL
.	NULL

Guerne	NULL
.	NULL

1997	NULL
.	NULL

Circulating	NULL
levels	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
soluble	NULL
receptors	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
are	NULL
significantly	NULL
higher	NULL
than	NULL
in	NULL
other	NULL
rheumatic	NULL
diseases	NULL
and	NULL
correlate	NULL
with	NULL
disease	NULL
activity	NULL
.	NULL

J	NULL
Rheumatol	NULL
.	NULL

24:303-308	NULL
.	NULL

Cope	NULL
,	NULL
A.P	NULL
.	NULL

,	NULL
D.	NULL
Aderka	NULL
,	NULL
M.	NULL
Doherty	NULL
,	NULL
H.	NULL
Engelmann	NULL
,	NULL
D.	NULL
Gib-bons	NULL
,	NULL
A.C.	NULL
Jones	NULL
,	NULL
F.M	NULL
.	NULL

Brennan	NULL
,	NULL
R.N	NULL
.	NULL

Maini	NULL
,	NULL
D.	NULL
Wallach	NULL
,	NULL
and	NULL
M.	NULL
Feldmann	NULL
.	NULL

1992	NULL
.	NULL

Increased	NULL
levels	NULL
of	NULL
soluble	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptors	NULL
in	NULL
the	NULL
sera	NULL
and	NULL
synovial	NULL
fluid	NULL
of	NULL
patients	NULL
with	NULL
rheumatic	NULL
diseases	NULL
.	NULL

A	NULL
#	NULL
thrfis	NULL
Rheum	NULL
.	NULL

35:1160-1169	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

Godfried	NULL
,	NULL
M.H	NULL
.	NULL

,	NULL
T.	NULL
Van	NULL
der	NULL
Poll	NULL
,	NULL
J.	NULL
Jansen	NULL
,	NULL
J.A	NULL
.	NULL

Romijin	NULL
,	NULL
J.K.	NULL
Schattenkerk	NULL
,	NULL
E.	NULL
Endert	NULL
,	NULL
S.J	NULL
.	NULL

Van	NULL
Deventer	NULL
,	NULL
and	NULL
H.P	NULL
.	NULL

Sauerwein	NULL
.	NULL

1993	NULL
.	NULL

Soluble	NULL
receptors	NULL
for	NULL
tumour	NULL
necrosis	NULL
fac-tor	NULL
:	NULL
a	NULL
putative	NULL
marker	NULL
of	NULL
disease	NULL
progression	NULL
in	NULL
HIV	NULL
infection	NULL
.	NULL

AIDS	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

7:33-36	NULL
.	NULL

Aderka	NULL
,	NULL
D.	NULL
,	NULL
P.	NULL
Sorkine	NULL
,	NULL
S.	NULL
Abu-Abid	NULL
,	NULL
D.	NULL
Lev	NULL
,	NULL
A.	NULL
Setton	NULL
,	NULL
A.P	NULL
.	NULL

Cope	NULL
,	NULL
D.	NULL
Wallach	NULL
,	NULL
and	NULL
J.	NULL
Klausner	NULL
.	NULL

1998	NULL
.	NULL

Shedding	NULL
kinetics	NULL
of	NULL
soluble	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
receptors	NULL
after	NULL
systemic	NULL
TNF	NULL
leaking	NULL
during	NULL
isolated	NULL
limb	NULL
perfusion	NULL
.	NULL

Relevance	NULL
to	NULL
the	NULL
pathophysiology	NULL
of	NULL
septic	NULL
shock	NULL
.	NULL

J	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

101	NULL
:	NULL
650-659	NULL
.	NULL

Bohrer	NULL
,	NULL
H.	NULL
,	NULL
F.	NULL
Qiu	NULL
,	NULL
T.	NULL
Zimmermann	NULL
,	NULL
Y.	NULL
Zhang	NULL
,	NULL
T.	NULL
Jimer	NULL
,	NULL
D.	NULL
Mannel	NULL
,	NULL
B.W	NULL
.	NULL

Bottiger	NULL
,	NULL
D.M	NULL
.	NULL

Stern	NULL
,	NULL
R.	NULL
Waldherr	NULL
,	NULL
HD	NULL
.	NULL

Saeger	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

R	NULL
ole	NULL
of	NULL
NF-KB	NULL
in	NULL
the	NULL
mortality	NULL
of	NULL
sepsis	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

100:972-985	NULL
.	NULL

Diez-Ruiz	NULL
,	NULL
A.	NULL
,	NULL
G.P	NULL
.	NULL

Tilz	NULL
,	NULL
R.	NULL
Zangerle	NULL
,	NULL
G.	NULL
Baier-Bitterlich	NULL
,	NULL
H.	NULL
Wachter	NULL
,	NULL
and	NULL
D.	NULL
Fuchs	NULL
.	NULL

1995	NULL
.	NULL

Soluble	NULL
receptors	NULL
for	NULL
tumour	NULL
necrosis	NULL
factor	NULL
in	NULL
clinical	NULL
laboratory	NULL
diagnosis	NULL
Eur	NULL
J	NULL
Haematol	NULL
.	NULL

54:1-8	NULL
.	NULL

Pasparakis	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
G.	NULL
Kollias	NULL
.	NULL

1995	NULL
.	NULL

Production	NULL
of	NULL
cytokine	NULL
transgenic	NULL
and	NULL
knockout	NULL
mice	NULL
.	NULL

In	NULL
Cytokines	NULL
:	NULL
A	NULL
Practical	NULL
Ap-proach	NULL
.	NULL

F.	NULL
Balkwill	NULL
,	NULL
editor	NULL
.	NULL

IR	NULL
L	NULL
Press	NULL
,	NULL
Oxford	NULL
,	NULL
UK	NULL
.	NULL

297-325	NULL
.	NULL

De	NULL
Togni	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
Goellner	NULL
,	NULL
N.H.	NULL
Ruddle	NULL
,	NULL
P.R	NULL
.	NULL

Streeter	NULL
,	NULL
A.	NULL
Fick	NULL
,	NULL
S.	NULL
Mariathasan	NULL
,	NULL
S.C.	NULL
Smith	NULL
,	NULL
R.	NULL
Carlson	NULL
,	NULL
LP	NULL
.	NULL

Shornick	NULL
,	NULL
J.	NULL
Strauss	NULL
Schoenberger	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
.	NULL

Abnormal	NULL
development	NULL
of	NULL
peripheral	NULL
lymphoid	NULL
organs	NULL
in	NULL
mice	NULL
deficient	NULL
in	NULL
lympho-toxin	NULL
.	NULL

Sdene	NULL
.	NULL

264:703-707	NULL
.	NULL

Kollias	NULL
,	NULL
G.	NULL
,	NULL
N.	NULL
Wrighton	NULL
,	NULL
J.	NULL
Hurst	NULL
,	NULL
and	NULL
F.	NULL
Grosveld	NULL
.	NULL

1986	NULL
.	NULL

Regulated	NULL
expression	NULL
of	NULL
human	NULL
*y-	NULL
,	NULL
B-	NULL
,	NULL
and	NULL
hybrid	NULL
yB-globin	NULL
genes	NULL
in	NULL
transgenic	NULL
mice	NULL
:	NULL
manipulation	NULL
of	NULL
the	NULL
developmental	NULL
expression	NULL
patterns	NULL
.	NULL

Cell	NULL
.	NULL

46:89-94	NULL
.	NULL

Grell	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
Scheurich	NULL
,	NULL
A	NULL
.	NULL

Meager	NULL
,	NULL
and	NULL
K.	NULL
Pfizenmaier	NULL
.	NULL

1993	NULL
.	NULL

TR	NULL
60	NULL
and	NULL
TR	NULL
80	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
-recep-tors	NULL
can	NULL
independently	NULL
mediate	NULL
cytolysis	NULL
.	NULL

Lymphokine	NULL
Cyto	NULL
kine	NULL
Res	NULL
.	NULL

12:143-148	NULL
.	NULL

Bemelmans	NULL
,	NULL
M.H	NULL
.	NULL

,	NULL
D.J	NULL
.	NULL

Gouma	NULL
,	NULL
and	NULL
W.A	NULL
.	NULL

Buurman	NULL
.	NULL

1993	NULL
.	NULL

LPS-induced	NULL
sTNF-receptor	NULL
release	NULL
in	NULL
vivo	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
.	NULL

Investigation	NULL
of	NULL
the	NULL
role	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
,	NULL
IL-1	NULL
,	NULL
leukemia	NULL
inhibitory	NULL
factor	NULL
,	NULL
and	NULL
IFN-y	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

151	NULL
:	NULL
5554-5562	NULL
.	NULL

Tomonari	NULL
,	NULL
K.	NULL
1988	NULL
.	NULL

A	NULL
rat	NULL
antibody	NULL
against	NULL
a	NULL
structure	NULL
functionally	NULL
related	NULL
to	NULL
the	NULL
mouse	NULL
T-cell	NULL
receptor/	NULL
T3	NULL
complex	NULL
.	NULL

Immunogenetics	NULL
.	NULL

28:455-458	NULL
.	NULL

Dignam	NULL
,	NULL
J.D	NULL
.	NULL

1990	NULL
.	NULL

Preparation	NULL
of	NULL
extracts	NULL
from	NULL
higher	NULL
eu-karyotes	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

182:194-203	NULL
.	NULL

Bradford	NULL
,	NULL
M.M	NULL
.	NULL

1976	NULL
.	NULL

A	NULL
rapid	NULL
and	NULL
sensitive	NULL
method	NULL
for	NULL
the	NULL
quantitation	NULL
of	NULL
microgram	NULL
quantities	NULL
of	NULL
protein	NULL
utilizing	NULL
the	NULL
principle	NULL
of	NULL
protein-dye	NULL
binding	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

72:248-254	NULL
.	NULL

Tartaglia	NULL
,	NULL
L.A.	NULL
,	NULL
D.V	NULL
.	NULL

Goeddel	NULL
,	NULL
C.	NULL
Reynolds	NULL
,	NULL
LS	NULL
.	NULL

Figari	NULL
,	NULL
R	NULL
.F	NULL
.	NULL

Weber	NULL
,	NULL
B.M	NULL
.	NULL

Fendly	NULL
,	NULL
and	NULL
M.A	NULL
.	NULL

Palladino	NULL
,	NULL
Jr.	NULL
1993	NULL
.	NULL

Stimulation	NULL
of	NULL
human	NULL
T-cell	NULL
proliferation	NULL
by	NULL
specific	NULL
activation	NULL
of	NULL
the	NULL
75-kDa	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

151	NULL
:	NULL
4637-4641	NULL
.	NULL

Bemelmans	NULL
,	NULL
M.H.A	NULL
.	NULL

,	NULL
D.J	NULL
.	NULL

Gouma	NULL
,	NULL
and	NULL
W.A	NULL
.	NULL

Buurman	NULL
.	NULL

1993	NULL
.	NULL

Influence	NULL
of	NULL
nephrectomy	NULL
on	NULL
tumor	NULL
necrosis	NULL
factor	NULL
clearance	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

150:2007-2017	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.A	NULL
.	NULL

,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1996	NULL
.	NULL

NF-kB	NULL
:	NULL
ten	NULL
years	NULL
af-ter	NULL
.	NULL

Cell	NULL
.	NULL

87:13-20	NULL
.	NULL

Rothe	NULL
,	NULL
M.	NULL
,	NULL
V.	NULL
Sarma	NULL
,	NULL
V.M	NULL
.	NULL

Dixit	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1995	NULL
.	NULL

TR	NULL
AF2-mediated	NULL
activation	NULL
of	NULL
NF-kB	NULL
by	NULL
TNF	NULL
receptor	NULL
2	NULL
and	NULL
CD40	NULL
.	NULL

Saene	NULL
.	NULL

269:1424-1427	NULL
.	NULL

1352	NULL
46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

Aderka	NULL
,	NULL
D.	NULL
,	NULL
H.	NULL
Englemann	NULL
,	NULL
V.	NULL
Hornik	NULL
,	NULL
Y.	NULL
Skornick	NULL
,	NULL
Y.	NULL
Levo	NULL
,	NULL
D.	NULL
Wallach	NULL
,	NULL
and	NULL
G.	NULL
Kushtai	NULL
.	NULL

1991	NULL
.	NULL

Increased	NULL
serum	NULL
levels	NULL
of	NULL
soluble	NULL
receptors	NULL
for	NULL
tumor	NULL
necrosis	NULL
factor	NULL
in	NULL
cancer	NULL
patients	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

51:5602-5607	NULL
.	NULL

Aderka	NULL
,	NULL
D.	NULL
1996	NULL
.	NULL

The	NULL
potential	NULL
biological	NULL
and	NULL
clinical	NULL
significance	NULL
of	NULL
the	NULL
soluble	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptors	NULL
.	NULL

Cytokine	NULL
Growth	NULL
Fador	NULL
R	NULL
ev	NULL
.	NULL

7:231-240	NULL
.	NULL

Peschon	NULL
,	NULL
J.J.	NULL
,	NULL
D.S	NULL
.	NULL

Torrance	NULL
,	NULL
K.L	NULL
.	NULL

Stocking	NULL
,	NULL
M.B	NULL
.	NULL

Glaccum	NULL
,	NULL
C.	NULL
Otten	NULL
,	NULL
C.R	NULL
.	NULL

Willis	NULL
K.	NULL
Charrier	NULL
,	NULL
P.J	NULL
.	NULL

Morrissey	NULL
,	NULL
C.B	NULL
.	NULL

Ware	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Mohler	NULL
.	NULL

1998	NULL
.	NULL

TNF	NULL
receptor-deficient	NULL
mice	NULL
reveal	NULL
divergent	NULL
roles	NULL
for	NULL
p55	NULL
and	NULL
p75	NULL
in	NULL
several	NULL
models	NULL
of	NULL
inflammation	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

160:943-952	NULL
.	NULL

Lucas	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Juillard	NULL
,	NULL
E.	NULL
Decoster	NULL
,	NULL
M.	NULL
Redard	NULL
,	NULL
D.	NULL
Burger	NULL
,	NULL
Y.	NULL
Donati	NULL
,	NULL
C.	NULL
Giroud	NULL
,	NULL
C.	NULL
Monso-Hinard	NULL
,	NULL
T.	NULL
De	NULL
Kesel	NULL
,	NULL
W.A	NULL
.	NULL

Buurman	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Crucial	NULL
role	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
receptor	NULL
2	NULL
and	NULL
membrane-bound	NULL
TNF	NULL
in	NULL
experimental	NULL
cerebral	NULL
malaria	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

27:1719-1725	NULL
.	NULL

Wang	NULL
,	NULL
B.	NULL
,	NULL
H.	NULL
Fujisawa	NULL
,	NULL
L.	NULL
Zhuang	NULL
,	NULL
S.	NULL
Kondo	NULL
,	NULL
G.M	NULL
.	NULL

Shivji	NULL
,	NULL
C.S	NULL
.	NULL

Kim	NULL
,	NULL
T.W	NULL
.	NULL

Mak	NULL
,	NULL
and	NULL
D.N	NULL
.	NULL

Sauder	NULL
.	NULL

1997	NULL
.	NULL

Depressed	NULL
langerhans	NULL
cell	NULL
migration	NULL
and	NULL
reduced	NULL
contact	NULL
hypersensitivity	NULL
response	NULL
in	NULL
mice	NULL
lacking	NULL
TNF	NULL
receptor	NULL
p75	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

159:6148-6155	NULL
.	NULL

Zheng	NULL
,	NULL
L.	NULL
,	NULL
G.	NULL
Fisher	NULL
,	NULL
R	NULL
.E	NULL
.	NULL

Miller	NULL
,	NULL
J.	NULL
Peschon	NULL
,	NULL
D.H.	NULL
Lynch	NULL
,	NULL
and	NULL
M.J.	NULL
Lenardo	NULL
.	NULL

1995	NULL
.	NULL

Induction	NULL
of	NULL
apoptosis	NULL
in	NULL
mature	NULL
T	NULL
cells	NULL
by	NULL
tumour	NULL
necrosis	NULL
factor	NULL
.	NULL

Nature	NULL
.	NULL

377:348-351	NULL
.	NULL

Tartaglia	NULL
,	NULL
L.A.	NULL
,	NULL
D.	NULL
Pennica	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1993	NULL
.	NULL

Ligand	NULL
passing	NULL
:	NULL
the	NULL
75-kDa	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
INF	NULL
)	NULL
receptor	NULL
recruits	NULL
TNF	NULL
for	NULL
signaling	NULL
by	NULL
the	NULL
55-kDa	NULL
TNF	NULL
receptor	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:18542-18548	NULL
.	NULL

Weiss	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Grell	NULL
,	NULL
B.	NULL
Hessabi	NULL
,	NULL
S.	NULL
Bourteele	NULL
,	NULL
G.	NULL
Muller	NULL
,	NULL
P.	NULL
Scheurich	NULL
,	NULL
and	NULL
H.	NULL
Wajant	NULL
.	NULL

1997	NULL
.	NULL

Enhancement	NULL
of	NULL
TNF	NULL
receptor	NULL
p60-mediated	NULL
cytotoxicity	NULL
by	NULL
TNF	NULL
receptor	NULL
p80	NULL
:	NULL
requirement	NULL
of	NULL
the	NULL
TNF	NULL
receptor-associated	NULL
factor-2	NULL
binding	NULL
site	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

158:2398-2404	NULL
.	NULL

Wells	NULL
,	NULL
J.A	NULL
.	NULL

1994	NULL
.	NULL

Structural	NULL
and	NULL
functional	NULL
basis	NULL
for	NULL
hormone	NULL
binding	NULL
and	NULL
receptor	NULL
oligomerization	NULL
.	NULL

Cur	NULL
:	NULL
Opin	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:163-173	NULL
.	NULL

Pinckard	NULL
,	NULL
JK	NULL
.	NULL

,	NULL
K.C	NULL
.	NULL

Sheehan	NULL
,	NULL
and	NULL
RD	NULL
.	NULL

Schreiber	NULL
.	NULL

1997	NULL
.	NULL

Ligand-	NULL
induced	NULL
formation	NULL
of	NULL
the	NULL
p55	NULL
and	NULL
p75	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
heterocomplexes	NULL
on	NULL
intact	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chen	NULL
.	NULL

272:10784-10789	NULL
.	NULL

Rao	NULL
,	NULL
P.	NULL
,	NULL
K.C	NULL
.	NULL

Hsu	NULL
,	NULL
and	NULL
M.V	NULL
.	NULL

Chao	NULL
.	NULL

1995	NULL
.	NULL

Upregulation	NULL
of	NULL
NF-kB	NULL
dependent	NULL
gene	NULL
expression	NULL
mediated	NULL
by	NULL
the	NULL
p75	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
.	NULL

J	NULL
Interferon	NULL
Cytokine	NULL
Res	NULL
.	NULL

15	NULL
:	NULL
171-177	NULL
.	NULL

Boldin	NULL
,	NULL
M.P	NULL
.	NULL

,	NULL
LL	NULL
.	NULL

Mett	NULL
,	NULL
EE	NULL
.	NULL

Varfolomeev	NULL
,	NULL
I.	NULL
Chumakov	NULL
,	NULL
Y.	NULL
Shemer-	NULL
Avni	NULL
,	NULL
J.H	NULL
.	NULL

Camonis	NULL
,	NULL
and	NULL
D.	NULL
Wallach	NULL
.	NULL

1995	NULL
.	NULL

Self	NULL
as	NULL
sociation	NULL
of	NULL
the	NULL
``	NULL
death	NULL
domains	NULL
``	NULL
of	NULL
the	NULL
p55	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
receptor	NULL
and	NULL
Fay	NULL
APO1	NULL
prompts	NULL
signaling	NULL
for	NULL
TNF	NULL
and	NULL
Fay	NULL
APO	NULL
1	NULL
effects	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:387-391	NULL
.	NULL

Cheng	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1996	NULL
.	NULL

TANK	NULL
,	NULL
a	NULL
co-inducer	NULL
with	NULL
TRAF2	NULL
of	NULL
TNF-	NULL
and	NULL
CD4O0L-mediated	NULL
NF-KB	NULL
activation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

10:963-973	NULL
.	NULL

R	NULL
abizadeh	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Oh	NULL
,	NULL
LT.	NULL
Zhong	NULL
,	NULL
J.	NULL
Yang	NULL
,	NULL
C.M	NULL
.	NULL

Bitler	NULL
,	NULL
LL	NULL
.	NULL

Butcher	NULL
,	NULL
and	NULL
D.E	NULL
.	NULL

Bredesen	NULL
.	NULL

1993	NULL
.	NULL

Induction	NULL
of	NULL
apoptosis	NULL
by	NULL
the	NULL
low-affinity	NULL
NGF	NULL
receptor	NULL
.	NULL

Sdene	NULL
.	NULL

261:345-348	NULL
.	NULL

Haley	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
J.J.	NULL
Hsuan	NULL
,	NULL
and	NULL
M.D	NULL
.	NULL

Waterfield	NULL
.	NULL

1989	NULL
.	NULL

Analysis	NULL
of	NULL
mammalian	NULL
fibroblast	NULL
transformation	NULL
by	NULL
normal	NULL
and	NULL
mutated	NULL
human	NULL
EGF	NULL
receptors	NULL
.	NULL

Onagene	NULL
.	NULL

4:273-283.	NULL
.	NULL

Grau	NULL
,	NULL
G.E	NULL
.	NULL

,	NULL
and	NULL
D.N	NULL
.	NULL

Maennel	NULL
.	NULL

1997	NULL
.	NULL

TNF	NULL
inhibition	NULL
and	NULL
sounding	NULL
a	NULL
cautionary	NULL
note	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

3:1193-1195	NULL
.	NULL

Multi-	NULL
Organ	NULL
Inflammation	NULL
by	NULL
Increased	NULL
Expression	NULL
of	NULL
the	NULL
D75STNF-R	NULL

